Patent Grant
11883658
The embodiments of this disclosure generally relate to methods, systems, and devices for the diagnosis, mitigations, and treatment of cognitive injury (e.g. mechanical ventilation induced delirium, stroke, concussion, etc.). In some examples, the present disclosure is directed to a method of reducing the occurrence of brain cell damage or death in a subject. One exemplary aspect is directed to a method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia/ischemia condition, brain inflammation condition, or a traumatic brain injury (TBI) event. Another exemplary aspect is directed to devices, systems, and methods for reducing brain and/or cognitive injury in patients on mechanical ventilation. Yet another exemplary aspect is directed to mitigating diaphragm muscle, lung, and brain injury.
Critical care patients, particularly those requiring invasive mechanical ventilation (MV), often experience higher levels of diaphragm, lung, brain, and other organ injury. The diaphragm muscle may rapidly lose muscle mass and strength. The lungs may suffer from ventilator-induced trauma. Cognitive effects may be caused by several factors including aberrant neuro-signaling and inflammatory responses. Patients presenting with existing cognitive injury such as, for example, from a traumatic (e.g. concussion) or ischemic (e.g. stroke) brain event may be at an even greater risk for rapid cognitive deterioration once placed on MV. There remains a need for cost-effective, practical, surgically simple and minimally invasive apparatus and methods that may reduce diaphragm, lung, and cognitive injury (e.g. delirium, dementia, and cognitive dysfunction, etc.) in ICU patients, particularly for those patients on MV.
During natural breathing, the diaphragm and other respiratory muscles contract to create a region of negative pressure outside the lungs. The lungs expand to equalize pressure, and air naturally flows into the lungs. When air is flowing into the lungs, this is inhalation, the act of breathing in. Most mechanical ventilators help patients breathe by assisting the inhalation of oxygen into the lungs and the exhalation of carbon dioxide by using positive pressure to periodically pressurize and/or inflate the lungs. While lifesaving in many respects, MV may also be detrimental.
For example, MV may induce Ventilator Induced Lung Injury (VILI), including, for example, volutrauma, atelectrauma, and biotrauma. Volutrauma is damage from over-distension of the lung parenchyma, which may result from high tidal volume and/or low lung compliance. Atelectrauma may result from recruitment-decruitment of collapsed alveoli during each ventilator cycle, generally a result of low tidal volume (Vt), low pressure, or inadequate levels of Positive End Expiratory Pressure (PEEP). Biotrauma is the expression of a local inflammatory process and may be characterized by the release of inflammatory mediators because of over-distending tidal volumes and repetitive opening and closing of unstable lung units.
Lung injury may lead to the activation of inflammatory genes and the release of inflammatory mediators from cells in the lungs. Cyclic stretch (CS) of the lung tissue may cause inflammatory cell infiltration, which may contribute to loss of capillary-alveolar barrier function, increased expression of pro-inflammatory mediators, including tumor necrosis factor-α and IL-6, and induction of cellular apoptosis. As free inflammatory mediators originating from the lungs circulate through the organs of the body, the free inflammatory mediators may impair oxygen delivery and may lead to organ failure. MV may contribute to compartmentalization of lung inflammatory response leading to multiple organ dysfunction syndromes. Thus, MV induced stress and strain in the lungs may result in inflammatory response of the alveoli, recruitment of neutrophils to lung parenchyma, and the production of cytokines. This process may then spread into intravascular circulation systems, and may reach distal organs, such as, for example, the brain.
Further, the lungs may sense the MV induced mechanical stimuli by mechanoreceptors, and the lung may communicate this information to the brain, via the autonomic nervous system. The diaphragm has significant sensory innervations.
Generally, the goals of mechanical ventilation are to provide precise control of the respiratory variables, such as, for example, partial pressure of arterial oxygen (PaO2) and partial pressure of arterial carbon dioxide (PaCO2) control. The mechanical ventilator may cyclically pressurize the lungs to provide effective gas exchange. It is important to balance goals with minimizing lung stretch and minimizing lower lung collapse. The unique lung volume, lung compliance, and gas exchange requirements for each patient may complicate these goals.
Decreased tidal volumes may lead to hypercapnia (increased PaCO2). Hypercapnia may lead to intracranial hypertension. Improved systemic oxygenation may reduce brain hypoxic insults. However, excessively high ventilator pressures may lead to systemic inflammatory response, which, in turn, may affect cerebral oxygenation and metabolism, thereby inducing brain injury.
PEEP may be used to recruit previously collapsed alveoli, improve arterial oxygenation, and reduce elastance of the respiratory system. However, PEEP may be detrimental to gas exchange, decrease cardiac output by reducing aortic blood flow/pressure, and may lead to barotrauma.
Protective mechanical ventilation with moderate to lower tidal volumes (e.g. 6 mL/kg), limiting plateau pressure <30 cm H2O, and utilizing PEEP of 10 cm H2O versus higher Vt and no PEEP may lead to less lung inflammation and reduce mortality. However, a single ventilation approach likely does not fit all scenarios. Even for a single patient, it may be difficult to balance diaphragm protection, lung protection, and brain protection, and provide adequate gas exchange for the patient. As such, clinicians may be forced to use balanced approaches, making tradeoffs and accepting potential injury to one organ while reducing the likelihood of injury to another organ.
Thus, there remains a need to limit or reverse lung injury for mechanically ventilated patients.
Although MV can be a life-saving intervention for patients suffering from respiratory failure, prolonged MV can promote diaphragmatic atrophy and contractile dysfunction (VIDD). This type of diaphragm injury and the accompanying diaphragm weakness may contribute to difficulty in weaning from MV.
The majority of patients treated with MV are readily liberated from ventilator support upon resolution of respiratory failure or recovery from surgery, but approximately one-third of patients encounter challenges with regaining the ability to breathe spontaneously. The prognosis may be favorable for patients who wean from MV successfully at the first attempt, but is less so for the remaining patients.
To date, there remains an unmet need to limit or reverse the diaphragm injury for mechanically ventilated patients.
The diaphragm muscle is an important crossroad for information involving the entire body. In addition to serving as the primary respiratory muscle, it has links throughout the body as part of an information network necessary for breathing. The diaphragm has significant sensory innervations. Both the phrenic and vagus nerves are part of this network, and each nerve contains both sensory and motor fibers. As an example, the vagus nerve which innervates the crural region of the diaphragm, can directly affect the system of reciprocal tension membranes (e.g. dura), producing a range of relevant symptoms in the body. In a similar mechanism, the event of diaphragmatic dysfunction can lead to a cascade of signaling events, which affect the brain and other organs. As both vagus and phrenic nerves innervate the diaphragm muscle, stimulation of either the vagus or phrenic nerve can affect a signaling cascade in the other. The potential implications of the stimuli on the brain, other body organs, and tissues will be discussed further below.
Both delirium and cognitive dysfunction occur in as many as 87% of the intensive care unit (ICU) patients when they are provided with pulmonary support via invasive MV (Ely E W et al., “Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU),” JAMA, 2001). While treatment methods have progressed, delirium and cognitive dysfunction remain a major problem in MV patients.
Aberrant neuro-signaling may lead to neurological, cellular, and inflammatory processes, which may lead to cognitive impairment during and after treatment with mechanical ventilation.
A vagotomy in subjects receiving MV may mitigate the increase in the levels of the dopamine-synthesizing enzyme and the degree of apoptosis in the hippocampus compared to control animals. This implies that the vagus nerve is sending a signal, related to MV, to cause the dopamine increase.
Critical care patients with a preexisting brain injury (e.g., stroke, TBI, acute ischemia, etc.), who are placed on mechanical ventilation, are at an increased risk for long term cognitive defects. Thus, there is a need for preventative or neuroprotective therapy that is efficacious in humans.
Inflammation is a common pathomechanism of acute lung injury and acute brain injury, affecting brain homeostasis. The inflammatory cascade following an acute brain injury may adversely affect the lungs, but evidence indicates that the opposite can occur as well. This can occur by means of a complex interaction between the autonomic, neuro-inflammatory, neuroendocrine, and immunologic pathways, which are physiologically programmed to preserve systemic homeostasis, but in certain circumstances may be responsible for harmful effects on remote organs and systems.
The lungs sense mechanical stimuli via mechanoreceptors, and the information is communicated to the brain via the autonomic nervous system. The afferent vagal nerves communicate information from pulmonary stretch receptors to the respiratory center in the brain. To date, there remains a need for effective treatments to help treat or mitigate both brain and lung injuries.
Afferent and efferent vagus nerves, α7 nAChR-expressing inflammatory cells, and central vagal nucleus in the brain form an inflammatory reflex that may control inflammation and immunity. Sensory neurons detect pathogens, damage, or injury via peripheral afferent vagal nerve endings and may then provide feedback to nucleus tractus solitarii (NTS) in the brain stem. The information is processed, and the efferent vagus nerve may transmit integrated information by action potentials to the celiac ganglion and then to other parts of the body.
The vagus nerve originates from medullar oblongata, which consists of four nuclei: dorsal nucleus, nucleus ambiguous, NTS, and spinal nucleus of trigeminal nerve. Approximately 80% of afferent sensory fibers are contained in the vagus nerve and are responsible for transmission of the information to the NTS. There are numerous afferent vagus nerve endings in the lungs and diaphragm. For example, lung information is transmitted via the afferent arm to NTS, a processing center, which is capable of differentiating types of infection, inflammation, or injury. The vagal nerve endings may synthesize and release Ach, which in turn activates α7 nAChR in the pro-inflammatory cells such as macrophages and neutrophils or epithelial cells to regulate the production of pro-inflammatory cytokines via NF-κB.
One mechanism for the transient ischemia protection involves the afferent vagal pathway. The vagus nerve consists of both afferent and efferent fibers with 80% of the afferent impulses originating in the thoracic and abdominal organs. The afferent activity is relayed to the NTS, which has projections to the locus coeruleus (LC) which controls the release of norepinephrine (NE) and 5-hydroxytryptamine (5-HT). NE activated by VNS may have anti-inflammatory effects and may stimulate the release of 5-HT. Data showing that agonists of 5-HT may reduce the release of glutamate in cerebral ischemia indicating the 5-HT attenuates excitotoxicity by inhibiting glutamate release. These afferent nerve pathway effects could contribute to the effectiveness of NVS in brain ischemia. Alternatively, the efferent vagal pathway may also induce neuroprotection via the cholinergic anti-inflammatory pathway (CAP) which is activated by the central cholinergic system in the brain via the efferent fiber of the vagus nerve.
Electrical stimulation of the vagus nerve leading to the activation of the CAP may suppress brain inflammation, leading to neuroprotection in ischemic stroke. The efferent vagus nerve stimulation can also inhibit a localized inflammatory cytokine cascade in tissues and organs that are served by efferent vagus nerve fibers.
When activated, the resident macrophages of the central nervous system (CNS), the microglia, may secrete molecules that cause neuronal dysfunction, or degeneration. It has further been discovered that stimulation of efferent vagus nerve fibers releases sufficient acetylcholine to mitigate a systemic inflammatory cytokine cascade, as occurs in endotoxic shock, or a localized inflammatory cytokine cascade.
Vagus nerve stimulation may cause up-regulation (expression) of α7 nAChR. The cellular and molecular mechanism for anti-inflammation may be partly attributable to acetylcholine (Ach), a neurotransmitter mainly released from vagus nerve endings. Activation of α7 nAChR by Ach on macrophages may suppress the release of pro-inflammatory cytokines in peripheral circulation, thereby preventing tissue damage via the inflammation reflex of the VN. The α7 nAChR receptors are commonly expressed in the brain including neurons glia and endothelial cells. Activation of these receptors may enhance neuronal resistance to ischemic or other types of insults.
An alternate technique to stimulate neural tissue, without the need for invasive procedures, is temporally interfering stimulation and involves crossing two high frequency electrical signals at the specific brain region to be stimulated. The two signals interfere with each other, resulting in a low frequency signal at the target area. Low frequency signals may provoke neurons to fire, while high frequency signals do not, so the targeted area may be activated while the surrounding tissue is not.
Embodiments of the present disclosure relate to, among other things, systems, devices, and methods for preventing, moderating, and/or treating brain injury. Each of the embodiments disclosed herein may include one or more of the features described in connection with any of the other disclosed embodiments.
This disclosure includes methods for treating a subject. In some aspects, the methods may include obtaining a test result reflecting a condition of a brain in the subject; determining a stimulation parameter based on the test result; and stimulating a nerve based on the stimulation parameter, wherein stimulation of the nerve assists or causes contraction of a respiratory muscle in the subject. In some examples, the nerve may be a phrenic nerve, and the respiratory muscle may be a diaphragm muscle.
In some examples, the nerve may be a first nerve, and the methods may further include stimulating a second nerve, wherein stimulation of the second nerve initiates a biological response in the brain that reduces a level of a causing factor of a brain injury. The second nerve may be a vagus nerve. The stimulation of the second nerve may affect signaling from the second nerve to the brain or a lung in the subject. The methods may further include stimulating a third nerve. In these cases, the second nerve may be a left vagus nerve, and the third nerve may be a right vagus nerve. In some cases, the nerve may be a first nerve, and the methods may further include inhibiting transmission of an aberrant signal by a second nerve.
In some examples, the second nerve may be stimulated by a nerve stimulator. For example, the second nerve may be stimulated by an external nerve stimulator. The external nerve stimulator may be positioned on a skin area adjacent to a vagus nerve in the subject. Alternatively or additionally, the second nerve may be stimulated by an implantable nerve stimulator. The second nerve may be stimulated by manual, mechanical, electrical, ultrasonic, or electromagnetic energy.
In some examples, the test result may be from imaging the brain. Alternatively or additionally, the test result may comprise a level of an inflammation- or pain-related protein in blood of the subject. The methods may further include performing a test that provides the test result.
In some examples, stimulating the nerve may include inserting a catheter with one or more electrodes in a blood vessel of the subject, and positioning the one or more electrodes proximate the nerve.
In some examples, the methods may further include ventilating the subject with a mechanical ventilator. In such cases, the test result may comprise an effect of ventilation on the brain. The methods may further include stimulating a second nerve during at least a portion of a ventilation inspiration period.
In some aspects, the methods of treating a subject may include stimulating a first nerve with a first stimulator to assist or cause contraction of a respiratory muscle in the subject; and stimulating a second nerve with the first stimulator or a second stimulator to reduce a level of a causing factor of a brain injury. The methods may further include stimulating a third nerve with the first stimulator, the second stimulator, or a third stimulator to assist or cause contraction of the respiratory muscle in the subject. The causing factor of the brain injury may be inflammation in the brain. The first nerve may be a phrenic nerve, and the second nerve may be a vagus nerve. The respiratory muscle may be a diaphragm muscle.
In some examples, the stimulation of the first nerve may be in synchrony with stimulation of the third nerve. Alternatively or additionally, the stimulation of the first nerve may be coordinated with stimulation of the second nerve. The stimulation the first nerve may be in synchrony with stimulation of the second nerve.
In some examples, the methods may further include ventilating the subject with a mechanical ventilator. The second nerve may be stimulated during at least a portion of a ventilation inspiration period.
In some example, the stimulation of the second nerve may be performed while the first nerve is not stimulated by the first stimulator. The first stimulator may comprise an intravascular catheter having a set of electrodes configured to stimulate a phrenic nerve. The second stimulator may comprise an intravascular catheter having a set of electrodes configured to stimulate a vagus nerve.
In some aspects, the methods for treating a subject may include stimulating a first nerve with a stimulator to assist or cause contraction of a respiratory muscle in the subject; obtaining a test result of a vagus nerve activity in the subject; generating a stimulation parameter based on test result; and stimulating at least one of the first nerve and a second nerve based on the stimulation parameter. The second nerve may be a vagus nerve, and stimulating at least one of the first nerve and the second nerve based on the stimulation parameter may include stimulating the second nerve based on the stimulation parameter. The first nerve may be a first phrenic nerve, and the second nerve may be a second phrenic nerve. In some cases, the test result may be obtained by testing heart blood flow, testing peripheral blood flow, testing blood pressure, imaging, or assessing inflammation- or pain-related molecules in blood of the subject.
The disclosure also includes systems. In some aspects, the systems may include a processor configured to: receive a test result reflecting a condition of a brain in a subject; and determine a stimulation parameter based on the test result; and a stimulator configured to stimulate a nerve based on the stimulation parameter, wherein stimulation of the nerve assists or causes contraction of a respiratory muscle in the subject. The systems may further include a mechanical ventilator. The systems may further include one or more switches operatively connected to the processor, the one or more switches being configured to regulate stimulation output to the stimulator.
In some examples, the systems may further include a sensor configured to detect a cardiac event, a respiratory event, a catheter location, a blood pressure, or a level of an inflammatory agent. The stimulator may be in communication with the sensor. The stimulator may comprise an intravascular catheter having a first set of electrodes configured to stimulate a right phrenic nerve and a second set of electrodes configured to stimulate a left phrenic nerve. The stimulator may be configured to affect signaling of a phrenic nerve, signaling of a vagus nerve, or a combination thereof.
In some aspects, the systems may include an electrode configured to stimulate a first nerve to assist or cause contraction of a respiratory muscle in the subject; and a stimulator configured to stimulate a second nerve to reduce a level of a causing factor of a brain injury. The stimulator may comprise an intravascular catheter having one or ore electrodes configured to stimulate a vagus nerve. The systems may further include a catheter configured for intravascular insertion, wherein the catheter comprises a first plurality of electrodes and a second plurality of electrodes.
In some aspects, the systems may include a first nerve stimulator configured to stimulate a first nerve, wherein stimulation of the first nerve assists or causes contraction of a respiratory muscle in the subject; and a processor configured to: receive a test result of a vagus nerve activity in the subject, and generate a stimulation parameter based on the test result; and a second nerve stimulator configured to stimulate a second nerve based on the stimulation parameter.
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate non-limiting embodiments of the present disclosure and together with the description serve to explain the principles of the disclosure.
Throughout the following description, specific details are set forth to provide a more thorough understanding to persons skilled in the art. The following description of examples of the technology is not intended to be exhaustive or to limit the system to the precise forms of any example embodiment. Accordingly, the description and drawings are to be regarded in an illustrative, rather than a restrictive, sense.
Further aspects of the disclosures and features of example embodiments are illustrated in the appended drawings and/or described in the text of this specification and/or described in the accompanying claims. It may be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. As used herein, the terms “comprises,” “comprising,” “including,” “having,” or other variations thereof, are intended to cover a non-exclusive inclusion such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements, but may include other elements not expressly listed or inherent to such a process, method, article, or apparatus. Additionally, the term “exemplary” is used herein in the sense of “example,” rather than “ideal.” As used herein, the terms “about,” “substantially,” and “approximately,” indicate a range of values within +/−15% of a stated value.
Reference will now be made in detail to examples of the present disclosure described above and illustrated in the accompanying drawings. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts.
The terms “proximal” and “distal” are used herein to refer to the relative positions of the components of an exemplary medical device or insertion device. When used herein, “proximal” refers to a position relatively closer to the exterior of the body or closer to an operator using the medical device or insertion device. In contrast, “distal” refers to a position relatively further away from the operator using the medical device or insertion device, or closer to the interior of the body.
In general, embodiments of this disclosure relate to systems, medical devices, and methods for electrically stimulating a patient's nerves, and preventing, modulating, controlling, or treating injury (e.g., injury of the brain, the lungs, or the diaphragm muscle). For example, the injury may be caused or enhanced by mechanical ventilation. As used herein, the term “injury” may refer to an alteration in cellular or molecular integrity, activity, level, robustness, state, or other alteration that is traceable to an event. For example, brain injury may be neuronal injury resulting from stress (repetitive stress), inflammation, oxidative stress, disease, pain, stroke, and/or physical injury such as surgery or trauma.
The methods herein may include stimulating one or more nerves, such as one or more phrenic nerves and/or one or more vagus nerves. For example, the methods may include stimulating one or more respiratory muscles (e.g., diaphragm muscle) or a portion thereof by stimulating one or more nerves (e.g., phrenic nerves). Stimulation of one or more phrenic nerves may play a role in preventing or treating brain injury (e.g., caused by mechanical ventilation). For example, in patients receiving mechanical ventilation, stimulation of phrenic nerves may pace the diaphragm muscle so that the pressure and time required from the mechanical ventilation are reduced. Alternatively or additionally, stimulation of phrenic nerves may initiate a response in the brain to reduce a causing factor of brain injury, such as inflammation. Stimulation of one or more vagus nerves may also initiate a response in the brain to reduce a causing factor of brain injury, such as inflammation. In some cases, the method may include blocking one or more vagus nerves so that the vagus nerve(s) does not transmit aberrant signals (e.g., signals that trigger inflammation in the brain) to the brain. The aberrant signals may result from mechanical ventilation.
The methods may further include monitoring, sensing, and/or testing one or more functions, activity, or other parameters of the brain, obtaining the results of the sensing or tests, and analyzing these results, for example, to determine the effect of the nerve stimulation and/or mechanical ventilation on brain function and/or activity. Based on the test results and their analysis, parameters (e.g., timing, duration, and profile such as intensity) for nerve stimulation may be generated or modified, and stimulation of nerves may be initiated or modified based on the parameters. Exemplary tests on brain function include magnetic resonance imaging (MRI) such as functional MRI, a computed tomography (CAT) scan, a positron emission tomography (PET) scan, a magnetoencephalography (MEG) scan, any other imaging or scanning modality, an electroencephalogram (EEG) test, detection of a cardiac event and/or a respiratory event, and/or measurement of blood pressure, intracranial pressure, cardiopulmonary pressure, brain oxygenation, and partial pressure of carbon dioxide in arterial blood (PaCO2). Brain oxygenation may be monitored in several ways including via jugular venous saturation, near-infrared spectroscopy, and/or microdialysis catheter assessment. Tests on brain function may also include laboratory tests of one or more bodily fluids (e.g., blood, urine, fluid surrounding the brain, etc.), or one or more tissues. The laboratory tests may detect levels of molecules (e.g., cytokines) indicative of brain injury or dysfunction, such as inflammation. Tests on brain function may further include neurological examinations (e.g., assessing of motor or sensory skills, like testing reflexes, eye movements, walking, and balance), and tissue biopsy. The tests may further include cognitive assessment (e.g., assessing mental status) by asking patients to conduct specific tasks and answer several questions, such as naming today's date or following a written instruction.
Alternatively or additionally, the methods may include testing the status of one or more nerve (e.g., vagus nerve) stimulations. In some cases, the methods may include testing brain function and the status of one or more nerve stimulations. Exemplary tests on the status of nerve (e.g., vagus nerve) stimulations include detection of electrodermal activity, heart rate variability, responses related to the control of pupil diameter and blood flow to the eye, peripheral blood flow (e.g., measured with laser Doppler flow meters), heart rate and blood pressure variability analysis, valsalva maneuver, deep metronomic breathing, a sustained handgrip test, a cold pressor test, a cold face test, active and passive orthostatic challenge maneuvers, blood pressure response to a mental arithmetic test, pharmacological baroreflex testing, a thermoregulatory sweat test, a quantitative sudomotor axon reflex test, magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), evaluation of electroencephalography (EEG) waveforms, the measurement of visual, audio and somatosensory evoked potentials, changes in absolute vital sign values, and changes in pain threshold. The tests may also include detecting chemistry (e.g., levels and activities of proteins or other molecules such as inflammation- or pain-related molecules) in the blood or other bodily fluids. The chemistry tests may include measuring the level and/concentrations of TNF-α, other cytokines, serotonin, gastrin, and/or norepinephrine.
The tests on brain function and/or vagus nerve stimulation may be performed prior to, during, or after ventilation or at different stages of ventilation. For example, the tests may be performed before, during, or after an inflation stage of mechanical ventilation. Alternatively or additionally, the tests may be performed before, during, or after stimulation of a nerve. Brain function and/or vagus nerve stimulation status or activity may be determined based on the test results. Alternatively or additionally, the results from the tests performed at different times may be compared to each other or to reference threshold values or ranges, e.g. thresholds or ranges that indicate normal brain function or other levels of brain function. In such cases, brain function and/or vagus nerve stimulation status may be determined based on the comparisons.
For a patient receiving or having received a nerve stimulation therapy, the brain function and/or vagus nerve stimulation status in the patient may be detected and compared to parameters indicative of normal function and/or status of the brain and/or the nerves. If a difference is determined, one or more parameters of nerve stimulation may be modified to adjust the nerve stimulation therapy administered to the patient. The adjustment may be performed continuously (e.g., based on real-time monitoring of brain function and/or vagus nerve stimulation status) for delivering optimal and personalized therapy to the patient.
In some cases, the methods may further include administering one or more drugs to the subject during the nerve stimulation, pacing, and/or ventilation procedure described herein. In embodiments, the drug therapy may be based on the analysis of any of the tests described above. In some cases, the one or more drugs may include those associated with decreased time to extubation and helpful in reducing brain injury. For example, the one or more drugs may include propofol and/or dexmedetomidine. In some cases, the one or more drugs may include those affecting smooth muscle tension and/or capable of reducing trachea-bronchial tone/tension. Such drugs may also help reduce pulmonary stretch receptor-induced aberrant vagus signaling responsible for brain injury.
The systems herein may include medical devices for performing the methods described in the disclosure. The medical device may include components such as a catheter having a tubular member and one or more electrode assemblies, a signal generator to provide stimulation energy to the electrode assemblies, one or more sensors to sense the condition of the patient and adjust the stimulation signals, and one or more control components allowing a user (e.g., a physician or a patient) to adjust the parameters of nerve stimulation. The different embodiments of the various medical device components may be combined and used together in any logical arrangement. Furthermore, individual features or elements of any described embodiment may be combined with or used in connection with the individual features or elements of other embodiments. The various embodiments may further be used in different contexts than those specifically described herein. For example, the disclosed electrode structures may be combined or used in combination with various deployment systems known in the art for various diagnostic and/or therapeutic applications.
The systems and methods disclosed in this disclosure may help to achieve at least one or more of the following to a patient: preventing, modulating, controlling, or treating brain injury, preventing, modulating, controlling, or treating lung injury, activating the diaphragm muscle (e.g., by stimulating phrenic nerves), or providing respiratory support or mechanical ventilation.
In some embodiments, the systems and methods herein may reduce and prevent brain injury (e.g., in patients receiving or have received mechanical ventilation) via phrenic or diaphragm stimulation. Electrical stimulation of at least one phrenic nerve and/or hemi-diaphragm during mechanical ventilation may provide effective O2/CO2 gas exchange while reducing upper lung barotrauma (stretch injury) and reducing atelectasis (lung collapse injury). Reducing lung injury may reduce the stimulus that leads to a cascade of events linked to brain inflammation and cognitive dysfunction. Electrical stimulation of one or more phrenic nerves or diaphragm muscle may result in stabilizing the afferent signaling to the brain to mitigate aberrant vagal signaling implicated in brain cell death. The diaphragm muscle activation by phrenic or other nerve/muscle stimulation may provide improved or stabilizing sensory input to brain receptors, compared to those sent during mechanical ventilation alone (e.g. thereby replacing the input typically received by the brain, as non-limiting examples from phrenic, vagus, or pulmonary stretch receptor signaling, during brain-driven diaphragm activation). The period of stimulation may vary since biological structures may prefer slight variation. The stimulation (e.g. phrenic, vagus, muscle, etc.) may be provided by a transvascular (e.g., transvenous) catheter, cuff electrodes, implanted electrodes, transcutaneous stimulators, or other suitable methods. For example, stimulation of vagus nerves may be provided by an external nerve stimulator, e.g., a stimulator positioned on a skin area adjacent to a vagus nerve. Alternatively or additionally, stimulation of vagus nerves may be provided by an implantable nerve stimulator.
In some embodiments, the systems and methods herein may reduce brain injury via vagus nerve block coordinated with mechanical ventilation-delivered breath. Electrical stimulation may be used to block the aberrant pain signals, e.g., by using a kilohertz frequency nerve block via vagus nerves, which may reduce inactivation of Akt (protein kinase B) and help mitigate cell death. Kilohertz frequency electrical stimulation could be delivered (e.g. at or about 40 kHz, or within a range of [1 kHz-100 kHz]) via electrodes placed on or near the vagus nerve (e.g., including a branch of the vagus nerve) to temporarily block afferent signals. The blocking signal may be designed to occur in synchrony with a specific phase (e.g., inspiration) of the mechanically delivered breath to minimize aberrant signaling. The blocking signal may be designed such that its intensity is modulated by one or more characteristics of the mechanical ventilation delivered breath (e.g., pressure, flow, tidal volume). The vagus-blocking signal may be delivered via transcutaneous electrodes, minimally invasively placed electrodes, transvenous electrodes, subcutaneous electrodes, direct contact electrodes, or other suitable delivery vehicle. The stimulation profile envelope of the blocking signal may be tailored to minimize the passage of the aberrant vagus signaling to the brain caused, for example, by the pulmonary stretch pain receptors. In one embodiment, the systems may include a sensor for adjusting the timing, duration, and profile of the nerve block signal to optimize the blockade of the aberrant signal. Sensors or other inputs may be used to trigger the blocking signal. For example, in one embodiment, the detection of breaths (e.g. coming from the mechanical ventilator) may be used to coordinate/synchronize stimulation of the phrenic nerve(s) and/or stimulation of the vagus nerve(s) with the mechanical ventilator. One such sensor includes a mechanical transducer placed on the patient's neck or throat (e.g. a microphone) that can detect the “pink noise” in the throat or endotracheal tube whenever a breath occurs. Alternatively, in another embodiment, a transducer may be attached in the airflow circuit (e.g. the inspiratory limb, where the inspiratory phase of the breath could be detected) or inserted or attached to a portion of the airflow circuit tubing. This may be used with an invasive or a non-invasive mechanical ventilator. In yet another embodiment, a mechanical transducer on a portion of the airflow circuit (e.g. a strain gauge) may serve as a stretch-detector that is clipped or wrapped around the tubing (either the inspiratory limb, or the tube that connects the wye-piece to the endotracheal tube). Changes in pressure associated with the breathing cycle may be detected by the mechanical transducer to synchronize stimulation.
In some embodiments, methods and systems herein may reduce diaphragm, lung, and brain injury via phrenic stimulation, and vagus nerve block coordinated with MV delivered breath. Stimulating at least one phrenic nerve may activate the diaphragm, which may stabilize aberrant signals sent to the brain via afferent neuro pathways, mitigating diaphragm atrophy, and reducing lung injury. The activation of diaphragm may also include stimulating at least one vagus nerve to block a signal. In one aspect, both left and right phrenic and vagus nerves may be stimulated. These stimulation signals may be delivered by one or more devices. A single catheter placed via the left (Internal Jugular) IJ or (External Jugular) EJ may stimulate the left vagus, left phrenic, and right phrenic nerve. In one aspect, an electrode population for sending the left vagus nerve block may be located proximal to the other electrode populations. In such an embodiment, the block may not prevent the distal phrenic signals from reaching the diaphragm muscle. The therapies may also be delivered by two or more separate devices. For example, an intravenous catheter placed in the jugular vein (internal or external) or subclavian vein may be used in combination with an external vagus stimulation device mounted on a neck collar, skin mounted transcutaneous device, or a set of electrodes placed percutaneously. The vagus nerve block may be timed to occur with the delivery of the mechanical ventilation breath, or with delivery of the phrenic nerve stimulation. A variety of sensors may be used to coordinate the stimulation with a patient's breathing or with the delivery of a breath from the mechanical ventilator. Sensors may sense heart rate, CO2, O2, breathing, temperature, motion, impedance, electromyography, electrocardiography, airflow, pressure, or any combination thereof.
In some embodiments, the methods and systems herein may reduce diaphragm injury, lung injury, and/or brain injury via phrenic stimulation, and/or vagus stimulation, and in some cases vagus nerve block coordinated with mechanical ventilation delivered breath. Electrical stimulation may also be used to deliver anti-inflammatory signaling via the vagus nerve. Low duty cycle signaling may be effective in providing long-term cerebral protection. In one embodiment, positive vagus pulse trains may be sent in between phrenic stimulation pulses. Alternatively or additionally, blocking pulses to the vagus nerve may be sent between positive stimulation pulses to the vagus nerve, or at the same time, or with portions of overlap. For example, positive (passivating) signals may be sent to the brain via the vagus nerve during the time between breaths, and the nerve block on the vagus nerve may be established when the mechanical ventilator is stretching the lungs to block the pain signal from reaching the brain. The blocking signal may be designed such that its intensity is modulated by one or more characteristics of the mechanical ventilation delivered breath (e.g., pressure, flow, tidal volume, etc.). The positive signal to the vagus may be designed such that its intensity is modulated by one or more characteristics of the mechanical ventilation delivered breath (e.g., inversely proportional to pressure, flow, tidal volume, etc.). In some cases, vagus nerve stimulation immediately after an ischemic event may be neuroprotective. For example, a patient may receive a pulse train delivered to a vagus nerve after a cerebral ischemic event. The pulse train may be interrupted to establish a nerve block when the ventilator is inflating the lungs, then the positive signal may be re-initiated between breaths. Alternatively or additionally, the positive signal may be sent continuously and it may be blocked by high frequency nerve block (e.g., every few seconds). In some cases, the positive signal does not have to been sent all the time or for long periods of time. For example, the positive signal may be sent once every few hours, or once a day.
Vagus stimulation may be transvascular, transdermal, or via minimally invasive electrodes placed in the proximity of the vagus nerve. Techniques may include selectively activating and/or blocking efferent and afferent neural pathways. This may involve simultaneous afferent vagus blocking and efferent phrenic stimulation. Another aspect includes a vagus stimulation device that delivers a nerve block during the inspiration phase of mechanical ventilation and then an anti-inflammatory stimulation signal to the vagus nerve at other time periods (e.g., a jugular catheter for vagus stimulation that synchronizes with the mechanical ventilation or with the phrenic nerve stimulation signal, delivering high frequency block when stretch receptors are activated and delivering anti-inflammation inducing signals other times).
In some embodiments, the methods and systems herein may reduce brain injury via phrenic pacing in mechanical ventilation patients. Aspects of the present disclosure may include systems and methods for reducing peak ventilator pressure, limiting end-inspiratory lung stretch to provide adequate ventilation while reducing lung inflammation, and reducing atelectrauma.
In some embodiments, the methods and systems herein may reduce brain injury by reducing the positive pressure required from external respiratory support and counteracting the effects of aberrant vagal signaling. Multiple means may be used to reduce the positive pressure, including iron lung, extracorporeal membrane oxygenation (ECMO), as well as phrenic nerve and respiratory muscle (e.g. diaphragm, intercostal, etc.) stimulation. Aberrant vagal signaling may be mitigated by any method used to reduce pulmonary stretch receptor activation as well as with vagus/phrenic stimulation or nerve block.
Referring to
In some examples, the stimulator devices (e.g., catheter 12) are readily applied to, or inserted into, the patient, temporary, and easily removed from the patient without the need for surgery at a later time. The stimulator, such as catheter 12 or other stimulation array, may be positioned internal to the patient via a percutaneous incision in the patient's neck. In some cases, the stimulator may be inserted proximate subclavian, femoral, or radial regions of the patient. In other examples, as described herein, the stimulator may be positioned external to the patient.
The various system components described herein may be combined and used together in any logical arrangement. Furthermore, individual features or elements of any described example may be combined with or used in connection with the individual features or elements of other embodiments. The various examples may further be used in different contexts than those specifically described herein. For example, the disclosed electrode structures may be combined or used in combination with various deployment systems known in the art for various diagnostic and/or therapeutic applications.
The remote controller 20 may include buttons 17, 19 that can be pressed by a patient or other user to control breathing patterns. In one example, pressing one of buttons 17, 19 can initiate a “sigh” breath, which may cause a greater volume of air to enter the patient's lungs than in a previous breath. A sigh breath may result when electrodes 34 of catheter 12 are directed to stimulate one or more of the phrenic nerves 26, 28 at a higher level than a normal breath (e.g., a stimulation train having a longer duration of stimulation or having pulses with a higher amplitude, pulse width, or frequency). Higher amplitude stimulation pulses can recruit additional nerve fibers, which in turn can engage additional muscle fibers to cause stronger and/or deeper muscle contractions. Extended pulse widths or extended durations of the stimulation train can deliver stimulation over longer periods of time to extend the duration of the muscle contractions. In the case of diaphragm muscle stimulation, longer pulse widths or extended duration of stimulation (train of pulses) have the potential to help expand the lower lung lobes by providing greater or extended negative pressure around the outside of the lungs. Such negative pressure has the potential to help prevent or mitigate a form of low pressure lung injury known as atelectasis. The increase in stimulation frequency can result in a more forceful contraction of the diaphragm 30. The increased stimulation (e.g., higher amplitude, pulse width, stimulation duration, or frequency) of the one or more phrenic nerves 26, 28 may result in a more forceful contraction of the diaphragm 30, causing the patient to inhale a greater volume of air, thereby providing a greater amount of oxygen to the patient. Sigh breaths may increase patient comfort.
In other examples, buttons 17, 19 may allow the patient or other user to start and stop stimulation therapy, or to increase or decrease stimulation parameters, including stimulation charge (amplitude×pulse width), frequency of pulses in a stimulation train, or breath rate. LED indicators or a small LCD screen (not shown) on the remote controller 20 or control unit 18 may provide other information to guide or inform the operator regarding the stimulation parameters, the feedback from the system sensors, or the condition of the patient.
Alternatively, a control unit having the functionality of control unit 18 can be implanted in the patient, along with catheter 12 as illustrated in
In yet another additional or alternative example, the control unit of system 100 may be portable. The portable control unit may include all of the functionality of control unit 18 of
The distal tip of catheter 12 may be a tapered distal end portion of catheter 12 and may have a smaller circumference than the body of catheter 12. The distal tip may be open at the distal end to allow a guide wire to pass through and distally beyond catheter 12. The distal tip may be softer than other portions of catheter 12, be atraumatic, and have rounded edges. Catheter 12 also may have one or more ports or openings in the sidewall of the catheter. A first opening may be located at a mid-portion of catheter 12 and other openings may be located near a proximal end of catheter 12. Each opening may be in fluid communication with respective lumens in catheter 12, through which fluid can be infused or extracted. The fluid may exit and/or enter the ports to be delivered into and/or from a blood vessel.
During use, a proximal portion of catheter 12 may be positioned in left subclavian vein 22, and a distal portion of catheter 12 may be positioned in superior vena cava 24. Positioned in this manner, electrodes 34 on the proximal portion of catheter 12 may be positioned proximate left phrenic nerve 26, and electrodes 34 on the distal portion of catheter 12 may be positioned proximate right phrenic nerve 28. As an alternative insertion site, catheter 12 may be inserted into a jugular vein e.g., left jugular vein 32 such as left external jugular vein or left internal jugular vein or right jugular vein 33 such as right external jugular vein or right internal jugular vein, and superior vena cava 24, such that the proximal electrodes are positioned to stimulate left phrenic nerve 26 and the distal electrodes are positioned to stimulate right phrenic nerve 28.
Left and right phrenic nerves 26, 28 may innervate diaphragm 30. Accordingly, catheter 12 may be positioned to electrically stimulate one or both of the left and right phrenic nerves 26, 28 to cause contraction of the diaphragm muscle 30 (or a portion thereof) to initiate or support a patient breath, help reduce the pressure from the mechanical ventilator, open up the lower lungs, reduce lung stretch/injury, and/or reduce aberrant brain signaling which may lead to cognitive injury.
In further examples, catheter 12 can be placed into and advanced through other vessels providing access to the locations adjacent the target nerve(s) (e.g., phrenic nerves), such as: the jugular, axillary, cephalic, cardiophrenic, brachial, or radial veins. In addition, the stimulator (e.g., catheter 12 or array 13) may use other forms of stimulation energy, such as ultrasound, to activate the target nerves. In some examples, the system 100 can target other respiratory muscles (e.g., intercostal) either in addition to, or alternatively to, the diaphragm 30. The energy can be delivered via one or more types of electrodes/methods including transvascular electrodes, subcutaneous electrodes, electrodes configured to be positioned in contact with the nerve (e.g., nerve cuffs), transdermal electrodes/stimulation, or other techniques known in the field.
The nerve stimulation systems and methods described herein may reduce or eliminate the need for a patient to receive external respiratory support. External respiratory support 88 in
Mechanical ventilation may refer to use of a ventilator to assist or replace spontaneous breathing. Mechanical ventilation is termed “invasive” if it involves any instrument penetrating through the mouth (such as an endotracheal tube) or the skin (such as a tracheostomy tube). There are two main types of mechanical ventilation: positive pressure ventilation, where air (or another gas mix) is forced into the trachea via positive pressure, and negative pressure ventilation, where air is drawn into (e.g., sucked into) the lungs (e.g., iron lung, etc.). There are many modes of mechanical ventilation. Mechanical ventilation may be indicated when the patient's spontaneous ventilation is unable to provide effective gas exchange in the lungs.
Ventilation also can be provided via a laryngeal mask airway (e.g., laryngeal mask), which is designed to keep a patient's airway open during anesthesia or unconsciousness. It is often referred to as a type of supraglottic airway. A laryngeal mask may include an airway tube that connects to an elliptical mask with a cuff, which is inserted through the patient's mouth and down the windpipe. Once deployed, the device may form an airtight seal on top of the glottis (unlike tracheal tubes, which pass through the glottis) to provide a secure or stable airway.
Non-invasive ventilation (NIV) is the use of airway support administered through a face (e.g., oral, nasal, nasal-oral) mask/cannula instead of an endotracheal tube. Inhaled gases are given with positive end-expiratory pressure, often with pressure support or with assist control ventilation at a set tidal volume and rate. This type of treatment is termed “non-invasive” because it is delivered with a mask or other means that is fitted to the face or nose, but without a need for tracheal intubation. Other forms of non-invasive ventilation include the use of external negative pressure systems such as is used in an iron-lung. Any device used to reduce the pressure outside the chest cavity or torso of a patient could effectively provide NIV.
Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilation, which applies mild air pressure on a continuous basis to keep the airways continuously open. CPAP may be used for patients who are able to breathe spontaneously on their own but may require a level of pressure support. It is an alternative to positive end-expiratory pressure (PEEP). Both modalities stent the lungs' alveoli open and therefore help recruit more of the lungs' surface area for ventilation. PEEP generally refers to devices that impose positive pressure only at the end of an exhalation. CPAP devices apply continuous positive airway pressure throughout the breathing cycle. Thus, the ventilator itself does not cycle during CPAP, no additional pressure above the level of CPAP is provided, and patients must initiate each breath on their own.
Bilevel Positive Airway Pressure (BiPAP) therapy is very similar in function and design to CPAP. BiPAPs can also be set to include a breath timing feature that measures the amount of breaths per minute a person should be taking. If the time between breaths exceeds the set limit, the machine can force the person to breath by temporarily increasing the air pressure. The main difference between BiPAP and CPAP machines is that BiPAP machines generally have two pressure settings: the prescribed pressure for inhalation (ipap), and a lower pressure for exhalation (epap). The dual settings allow the patient to move more air in and out of their lungs.
Extracorporeal membrane oxygenation (ECMO), which is also known as extracorporeal life support (ECLS), is an extracorporeal technique to provide prolonged cardiac and respiratory support to patients whose heart and lungs are unable to provide an adequate amount of gas exchange. The technology for ECMO is similar to that used during cardiopulmonary bypass, which is typically used to provide shorter-term support. During ECMO, blood is removed from the person's body and passed through a device, which removes carbon dioxide and provides oxygen to red blood cells. Long-term ECMO patients can often develop respiratory muscle weakness because of muscle inactivity and other causes. Certain therapy methods described herein may include delivering stimulation therapy to a patient receiving both ECMO and another form of external respiratory support. Certain therapy methods of this disclosure may utilize ECMO devices, which include a stimulation array, to deliver the described therapy.
In some examples, catheter 12 can be inserted into (and/or secured relative to) the patient. In many embodiments, catheter 12 may be removed from the patient's body when desired without the need for surgery. For example, catheter 12 of
The timing of stimulation of one or more nerves may be coordinated with the timing of ventilation. For example, a nerve (e.g., a vagus nerve) may be stimulated during at least a portion of a ventilation inspiration period.
Alternatively or additionally, timing of stimulation of multiple nerves may also be coordinated. For example, stimulation of a second nerve is performed while a first nerve is not stimulated by the one or more electrodes of a first plurality of the electrodes of the catheter. In some cases, stimulating one or more portions of a respiratory muscle (e.g., diaphragm muscle) may be stimulated when a nerve is not stimulated (e.g., when the nerve is blocked, or no stimulation is provided). In some cases, stimulation output from one or more nerve stimulation electrodes may occur in an inverse relationship to stimulation output from the two or more diaphragm stimulation electrodes. Alternatively or additionally, stimulation output from the one or more nerve stimulation electrodes may occur during stimulation output from the two or more diaphragm stimulation electrodes.
As shown in
As shown in
Windows on catheters may expose electrodes, allowing for a conductive path between sets or pairs of electrodes and surrounding tissue, including the blood vessel lumen in which catheter is inserted. Alternatively, electrodes could be printed onto the surface of the catheter by one of several known means (e.g. conductive inks, polymers, etc.). Further, the electrodes may be integrated into a flexible printed circuit, which can be attached to, or integrated into, the catheter. Insulation means known in the art would be used to ensure that the electrodes, and not any unwanted electrical elements, are exposed to direct contact with the patient.
In one example illustrated in
Referring to
Electrodes 34 may extend partially around the circumference of catheter 12. This “partial” electrode configuration may allow electrodes 34 to target a desired nerve for stimulation, while minimizing application of electrical charge to undesired areas of the patient's anatomy (e.g., other nerves or the heart). As shown in
Furthermore, the catheters described herein may include any features of the nerve stimulation devices and sensing devices described in the following documents, which are all incorporated by reference herein in their entireties: U.S. Pat. No. 8,571,662 (titled “Transvascular Nerve Stimulation Apparatus and Methods,” issued Oct. 29, 2013); U.S. Pat. No. 9,242,088 (titled “Apparatus and Methods for Assisted Breathing by Transvascular Nerve Stimulation,” issued Jan. 26, 2016); U.S. Pat. No. 9,333,363 (titled “Systems and Related Methods for Optimization of Multi-Electrode Nerve Pacing,” issued May 10, 2016); U.S. application Ser. No. 14/383,285 (titled “Transvascular Nerve Stimulation Apparatus and Methods,” filed Sep. 5, 2014); U.S. application Ser. No. 14/410,022 (titled “Transvascular Diaphragm Pacing Systems and Methods of Use,” filed Dec. 19, 2014); U.S. application Ser. No. 15/606,867 (titled “Apparatus And Methods For Assisted Breathing By Transvascular Nerve Stimulation,” filed May 26, 2017); or U.S. application Ser. No. 15/666,989 (titled “Systems And Methods For Intravascular Catheter Positioning and/or Nerve Stimulation,” filed Aug. 2, 2017). In addition, the control units described herein can have any of the functionality of the control units described in the above-referenced patent documents (e.g., the control units described herein can implement the methods of nerve stimulation described in the incorporated documents).
During nerve stimulation, one or more electrodes 34 may be selected from the proximal set 35 for stimulation of the left phrenic nerve 26, and one or more electrodes 34 may be selected from the distal set 37 for stimulation of right phrenic nerve 28. Catheter 12 may stimulate nerves using monopolar, bipolar, or tripolar electrode combinations, or using any other suitable combination of electrodes 34. In some examples, a second or third group of electrodes can be used to stimulate other respiratory muscles. In general, a stimulator or a stimulation array may include multiple sets of electrodes, with each set being configured to stimulate either the same or different nerves or muscles. When multiple nerves or muscles are being stimulated, the controllers and sensors described herein may be used to coordinate stimulation to achieve the desired muscle activation, breath, or level of respiratory support.
As illustrated in
Catheter 12, or other stimulation devices of this disclosure, may incorporate markings or other indicators on its exterior to help guide the positioning and orientation of the device. Catheter 12, or other stimulation devices of this disclosure, may also include internal indicators (e.g., radiopaque markers, contrast material such as barium sulfate, echogenic markers, etc.) visible by x-ray, ultrasound or other imaging technique to assist with positioning the stimulator in the desired location. Catheter 12 may include any combination of the features described herein. Accordingly, the features of catheter 12 are not limited to the specific combination shown in
Referring still to
The embodiment illustrated in
The dimensions of catheter 12 may be customized in accordance with the anatomy of a particular patient (e.g., different sizes of humans, pigs, chimpanzees, etc.). However, in some embodiments, the length of the section of the catheter that includes the proximal windows may be 16 cm or less, between 3 and 5 cm, or between 1 and 3 cm. The length of the section of the catheter that includes the distal windows may be 12 cm or less, between 2 and 4 cm, or between 1 and 2 cm. The distance between two adjacent windows (whether the windows are circumferentially adjacent or longitudinally adjacent on the same row of windows) may be 5 cm or less, 3 cm or less, may be around 1 cm, or may be less than 1 cm. These catheter dimensions are exemplary only, and the catheter may have dimensions that vary from the above ranges and specific measurements. Additionally, catheter 12 may include windows in different configurations than discussed above.
The catheter's distal tip may be a tapered distal end portion of catheter 12. The distal tip may be open at the distal end to allow a guide wire to pass through and distally beyond catheter. The distal tip may have a smaller circumference than the body of catheter, and may be softer than other portions of catheter, atraumatic, and have rounded edges.
The catheter may also have a ports 38a, 40a, 42a that are connected to an individual tube proximally 48, 50, 52 to act as one or more separate vascular lines (three as shown in
Once the catheter is fully inserted into the patient, various electrodes or electrode combinations may be tested to locate nerves of interest and to determine which electrodes most effectively stimulate the nerves of interest. For example, in one embodiment, testing may be done to locate the right phrenic nerve and to determine which group of distal electrodes in the distal electrode assemblies most effectively stimulate the right phrenic nerve. Similarly, testing may be done to locate the left phrenic nerve and to determine which group of proximal electrodes in the proximal electrode assemblies most effectively stimulate the left phrenic nerve. Similarly, testing may be done to locate the vagus nerve and to determine which group of electrodes in the electrode assemblies most effectively stimulate the vagus nerve.
This testing and nerve location may be controlled and/or monitored via control unit 14 or 14′, which may include testing programming and/or applications. For example, control unit 14 or 14′ may test the electrodes and electrode combinations to determine which combinations (e.g., bipolar, tripolar, quadrupolar, multipolar) of electrodes most effectively stimulate the targeted nerve, e.g., the right phrenic nerve, left phrenic nerve, and/or vagus nerve.
As a non-limiting example, testing could involve the use of a signal generator to systematically send electrical impulses to selected electrodes. By observing the patient's condition or by using sensors (either within or separate from the catheter), the desired stimulation electrodes may be identified. Electrodes may serve as both stimulating electrodes and as sensing electrodes, and the medical system may be integrated into a mechanical ventilator, which can be used to sense the patient's condition. Moreover, for example, the control unit may be programmed and/or activated to (a) select a first stimulation group of electrodes from the electrode assemblies to stimulate the left phrenic nerve, (b) select a second stimulation group of electrodes from the electrode assemblies to stimulate the right phrenic nerve, (c) select a third stimulation group of electrodes from the electrode assemblies to stimulate the vagus nerve (d) select a first stimulation current for the first stimulation group of electrodes to stimulate the left phrenic nerve, (e) select a second stimulation current for the second stimulation group of electrodes to stimulate the right phrenic nerve, and (f) select a third stimulation current for the third stimulation group of electrodes to stimulate the vagus nerve. The selection of electrodes and current levels may be pre-programmed or input based on the patient's characteristics, or the control unit may test different electrode groups and current levels and monitor the patient's response to determine the electrode pairs and current levels.
In some cases, the systems herein may include a transcutaneous noninvasive vagus nerve stimulator (nVNS) for stimulating a vagus nerve and/or a transcutaneous respiratory muscle stimulator. For example, devices that use electrical current from a small handheld or skin mounted device to stimulate a nerve in the neck or ear lobe may be used to stimulate a vagus nerve or stimulate nerves/muscles on the torso to activate a respiratory muscle. Alternatively or additionally, various other methods may be used to stimulate nerves, such as, for example, subcutaneous electrodes or nerve cuffs connected to the control unit.
When an electrical charge is delivered to the phrenic nerves, the diaphragm muscles may contract and generate negative pressure in the thoracic cavity. The lungs then expand to draw in a volume of air. This contraction of diaphragm muscles can be sensed manually by palpation or by placing a hand on the thoracic cavity, as shown in
Alternatively or additionally, system 200 of
The system may include a controller, which may be part of any of the control units described herein. Each of the components of the system may be operably coupled to the controller, and the controller may manage operation of electrodes during nerve stimulation, control the gathering of information by various sensors and electrodes, and control fluid delivery or extraction. It should be understood that the various modules described herein may be part of a computing system and are separated in
The electrodes may be electronically coupled to switching electronics, which may be communicably coupled to the controller. As shown in
The electrodes may be used for both electrically stimulating nerves and for gathering physiological information. When being used for nerve stimulation, a first combination of electrodes (e.g., one, two, three, or more electrodes) may be electrically coupled to a first stimulation module channel for stimulation of a first nerve (e.g., the right phrenic nerve) and a second combination of electrodes (e.g., one, two, three, or more electrodes) may be electrically coupled to a second stimulation module channel for stimulation of a second nerve (e.g., the vagus nerve). There may also be a third or fourth channel to stimulate more nerves or muscles. Electrical signals may be sent from the first and second stimulation module channels to the electrode combinations to cause the electrodes to stimulate the nerves. In other examples, more than two electrode combinations (e.g., 3, 4, or more) may be used to stimulate one or more target nerves, and the system may include more than two stimulation module channels.
The electrodes may be further configured to sense physiological information from a patient, such as nerve activity, ECG, or electrical impedance, as will be described further below. When being used for sensing, one or more of electrodes may be electronically coupled to a signal acquisition module. The signal acquisition module may receive signals from electrodes.
The switching electronics may selectively couple electrodes to first stimulation module channel, the second stimulation module channel, or the signal acquisition module. Switching electronics may change which electrodes are used for stimulation and which are used for sensing at any given time. In one example, any electrode can be used for nerve stimulation and any electrode can be used for sensing functions described herein. In other words, each electrode may be configured to stimulate nerves, and each electrode may be configured to sense physiological information.
The signal acquisition module may further be coupled to one or more sensors configured to gather physiological information from a patient. For example, the system may include one or more of a blood gas sensor or a pressure sensor. These sensors may be located in lumens of the catheter, outside of the patient in fluid communication with a lumen, on an outer surface of the catheter, or in any other suitable location. In one example, the blood gas sensor may be housed in or fluidly connected to a lumen, while the pressure sensor may be housed in or fluidly connected to another lumen. The blood gas sensor may measure the amount of O2 or CO2 in the patient's blood. The pressure sensor may measure the central venous pressure (CVP) of the patient.
The signal acquisition module may transmit the signals received from one or more of electrodes, the blood gas sensor, and/or the pressure sensor to the appropriate processing/filtering module of the system. For example, signals from the pressure sensor may be transmitted to a central venous pressure signal processing/filtering module, where the signals are processed and filtered to aid in interpretation of CVP information. Similarly, signals from the blood gas sensor may be transmitted to a blood gas signal processing/filtering module for processing and filtering to determine blood gas levels. Signals from electrodes, when they are used for sensing, may be sent to a nerve signal processing/filtering module, an ECG signal processing/filtering module, or an impedance signal processing/filtering module, as appropriate. Signals from electrodes or other sensors may be sent to an amplification module, if necessary, to amplify the signals prior to being sent to the appropriate processing/filtering module.
The systems and methods described herein may prevent, modulate, control, or treat brain injury while pacing the diaphragm. The brain injury may be caused by mechanical ventilation. The systems and methods may perform tests on a brain function and/or a status of vagus nerve stimulation. Based on the results of the tests, one or more phrenic nerves and/or vagus nerves may be stimulated. Stimulation of the nerves may reduce inflammation in the brain. Alternatively or additionally, one or more nerves (e.g., vagus) may be blocked using signals from electrodes to block aberrant signaling from the brain.
In one exemplary therapy session, catheter 12 may be positioned in the vasculature to extend adjacent or across the left and right phrenic nerves 26, 28. Appropriate distal and proximal electrode pairs may be selected to cause a contraction of the respiratory muscle, e.g., both the left and right hem i-diaphragm muscles. The operator (e.g., physician or patient) may set the stimulation pulse train length at about 1.2 seconds, a pulse amplitude to about 100% of a threshold value, and an initial pulse width to about 100% of a threshold value. Pulse parameters can be adjusted to achieve the desired level of muscle contraction and reduction in positive lung pressure from an external respiratory support device 88. The pulse width can be modulated between stimulation pulses in the stimulation pulse train. In some cases, the pulse amplitude can be modulated between stimulation pulses in the stimulation pulse train. Using the remote hand held controller 20, the operator may provide a therapy set of 10 stimulation pulse trains. In some examples, each of the stimulation pulse trains may be timed to coincide with a breath delivered by a mechanical ventilator or the patient's spontaneous breath.
In some embodiments, the system can communicate directly with a mechanical ventilator, or other external respiratory support system (e.g., external respiratory support 88), to coordinate the therapy delivery with the support provided by the external device. As previously described, sensors detecting activity from diaphragm muscles, nerves (e.g. phrenic nerves, vagus nerves, etc.) or other patient monitors or respiratory support devices can be used to trigger stimulation and/or breath delivery from a mechanical ventilator. Also, as a non-limiting example, the systems described herein may be operably connected (e.g., hardwired, wireless, etc.) to receive a signal from the mechanical ventilator indicating the initiation of a breath to the patient, and the systems can synchronize the delivery of the stimulation pulse train to coordinate with a desired phase of the breath. In another example, an operator may set the stimulation parameters and ask the patient to activate their breathing muscles. The operator may then coordinate the trigger of electrical stimulation with the patient efforts to provide maximum exercise of the muscles. In another example, external respiratory support 88 can be reduced or even eliminated during a portion of or all of the delivery of a stimulation set or stimulation session.
In some examples, 10 stimulations pulse trains are provided. The pulse trains can be timed to 10 sequential breaths, or the operator may skip one or more breaths to allow the patient to rest periodically between stimulations. After the 10 stimulation pulse trains are delivered, the patient may be allowed to rest for a period of time, for example 30 seconds to 5 minutes. After a suitable rest, the operator can initiate a second set, for example 10 breaths, again followed by a resting period. The operator can deliver several sets, e.g., 4 sets, that each includes 10 stimulations. Each stimulation may cause a muscle contraction, for a total of 40 muscle contractions over a 1- to 15-minute period. The desired number of stimulations for a session may be delivered in a single set, if needed. The patient may then be permitted to rest (e.g., for one or more hours), and in some cases at least 3 hours, and potentially as long as 24 or 48 hours before beginning another therapy session. In some instances, two to three, or more, therapy sessions are delivered each day. Regardless, the number of stimulations provided to the respiratory muscles may be a small fraction of the breaths required by the patient each day. In the previously-described example of 40 stimulations/day, the number of stimulations delivered is approximately less than 0.2% or about 0.2% of the breaths taken by or delivered to the patient per day.
In one example, the stimulation parameters may be kept the same from one stimulation that causes muscle contraction to the next stimulation, from one therapy set to the next therapy set, from one session to the next session, or from one day to the next day. In other examples, one of the parameters, such as the stimulation amplitude, the stimulation frequency, the stimulation hold time, or the resistance of the breathing circuit, may be increased or decreased between two stimulations that cause muscle contractions, between two sets, between two sessions, or between two days. The factors to consider while changing parameters may be patient tolerance, unintended stimulation of other structures, fatigue, or a desire for increased strength.
In another example of a therapy session, stimulation signals may be delivered over a total period of time of approximately 2 hours or less, during one or more therapy sessions during that total of 2 hours or less, during a 24-hour period. In another example, stimulation signals may be delivered over a total period of time of 5 hours or less during a 24-hour period.
In other examples of therapy sessions, stimulation signals may be delivered to contract one or more respiratory muscles for no more than: 20% of the breaths taken by or delivered to the patient in a 24-hour period; 10% of the breaths taken by or delivered to the patient in a 24-hour period; 2% of the breaths taken by or delivered to the patient in a 24-hour period; or 0.2% of the breaths taken by or delivered to the patient in a 24-hour period.
In another example, a brief stimulation therapy session lasting approximately 3 to 10 minutes may be delivered 12 to 24 times over a 24-hour period; 6 to 12 times over a 24-hour period; or once in a 24-hour period.
In another example, therapy sessions may be administered until the patient no longer requires external respiratory support; or up to 48 hours after the time at which the patient no longer requires, or is no longer receiving, external respiratory support.
Various examples of the subject disclosure may be implemented soon after the patient begins using external respiratory support (e.g., mechanical ventilation) to help reduce the loss of strength and or endurance of a respiratory muscle. Various examples of this disclosure can be used to help reduce the level of injury to a patient's lungs, heart, brain and/or other organs of the body. It is contemplated that a stimulation with every breath, or alternatively a majority of breaths, may provide a desired level of protection.
The systems described herein can be programmed to vary the profile of the stimulation pulse trains from time to time. For example, every tenth stimulation pulse train can be programmed to be longer than the others to produce a deeper or longer breath (e.g., sigh breath). In this case, the duration of the stimulation pulse train between two adjacent pulse trains will vary.
In some examples, therapy may be continued and steps related to activating the stimulator and ceasing activation of the stimulator may be repeated until MIP reaches a pre-determined value.
Furthermore, steps of any therapy treatment described herein may be carried out with respect to more than one nerve and more than one respiratory muscle. Stimulations of multiple nerves (and one or more respiratory muscles) may be synchronized so that the patient's muscle or muscles are stimulated at the same time. To achieve this synchronization, two or more combinations of selected electrodes may be activated at the same time during a therapy session. For example, if the first set of electrodes emits electrical signals up to 100 times, the second set of electrodes may emit electrical signals up to 100 times, with each emission of the second set corresponding to an emission of the first set of electrodes. In one example, the first and second sets of electrodes may be used to stimulate the left and right phrenic nerves to cause synchronized contractions of the left and right hemi-diaphragms. In another example, the first set may be used to stimulate the diaphragm, and the second set may be used to stimulate the intercostal muscles. The diaphragm and the intercostal muscles may be stimulated simultaneously. Alternatively, the diaphragm and the intercostal muscles may be stimulated out of phase. For example, when the external intercostal muscles are stimulated, the diaphragm may be stimulated simultaneously with the external intercostal muscles. When the internal intercostal muscles are stimulated, the diaphragm and the internal intercostal muscles may be stimulated out of phase. Both stimulations may occur at the same time in the patient breath cycle. In yet another example, the patient's nerves/muscles may be stimulated during an inspiratory period of the patient's ventilator or other external respiratory support.
While most examples described herein consider that a therapy session will be delivered by a health care professional, other approaches of therapy delivery may be utilized that also deliver infrequent respiratory muscle stimulation to build strength. As a non-limiting example, a closed-loop automated example of the system of this disclosure can be designed to deliver a stimulation to a respiratory muscle at a specific duty cycle such as 1 stimulation for every X breaths, where X could range from 10 to 1000. This approach may provide for periodic muscle stimulation with a predetermined number of resting breaths in between. X may be as small as 1 and as large as 10,000 in various examples. When using the systems and methods described herein to prevent respiratory muscle atrophy as well as lung and brain injury, the stimulations can be provided more frequently, potentially as often as every breath.
Various electrodes may be used to stimulate nerves and/or muscles as described in this disclosure. As examples, the stimulators described herein may include one or more of: nerve stimulation electrodes, endotracheal electrodes, endoesophageal electrodes, intravascular electrodes, transcutaneous electrodes, intracutaneous electrodes, electromagnetic beam electrodes, balloon-type electrodes, basket-type electrodes, umbrella-type electrodes, tape-type electrodes, suction-type electrodes, screw-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes, patch electrodes, cuff electrodes, clip electrodes, needle electrodes, or probe electrodes. Furthermore, the stimulation energy may be delivered by an energy form that includes at least one of mechanical, electrical, ultrasonic, photonic, or electromagnetic energy.
While principles of the present disclosure are described herein with reference to illustrative embodiments for particular applications, it should be understood that the disclosure is not limited thereto. Those having ordinary skill in the art and access to the teachings provided herein will recognize additional modifications, applications, embodiments, and substitution of equivalents all fall within the scope of the embodiments described herein. Accordingly, the invention is not to be considered as limited by the foregoing description.
This application is a continuation of U.S. patent application Ser. No. 16/022,897, filed Jun. 29, 2018, which claims priority to U.S. Provisional Patent Application No. 62/527,536, filed Jun. 30, 2017, which are incorporated by reference herein in their entireties. In general, all publications, patent applications, and patents mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual document was specifically individually indicated to be incorporated by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1693734 | Waggoner | Dec 1928 | A |
| 2532788 | Sarnoff | Dec 1950 | A |
| 2664880 | Wales, Jr. | Jan 1954 | A |
| 3348548 | Chardack | Oct 1967 | A |
| 3470876 | John | Oct 1969 | A |
| 3769984 | Muench | Nov 1973 | A |
| 3804098 | Friedman | Apr 1974 | A |
| 3817241 | Grausz | Jun 1974 | A |
| 3835864 | Rasor et al. | Sep 1974 | A |
| 3847157 | Caillouette et al. | Nov 1974 | A |
| 3851641 | Toole et al. | Dec 1974 | A |
| 3896373 | Zelby | Jul 1975 | A |
| 3938502 | Bom | Feb 1976 | A |
| 3983881 | Wickham | Oct 1976 | A |
| 4054881 | Raab | Oct 1977 | A |
| 4072146 | Howes | Feb 1978 | A |
| 4114601 | Abels | Sep 1978 | A |
| 4143872 | Havstad et al. | Mar 1979 | A |
| 4173228 | Childress et al. | Nov 1979 | A |
| 4249539 | Mezrich et al. | Feb 1981 | A |
| 4317078 | Weed et al. | Feb 1982 | A |
| 4380237 | Newbower | Apr 1983 | A |
| 4407294 | Vilkomerson | Oct 1983 | A |
| 4416289 | Bresler | Nov 1983 | A |
| 4431005 | McCormick | Feb 1984 | A |
| 4431006 | Trimmer et al. | Feb 1984 | A |
| 4445501 | Bresler | May 1984 | A |
| RE31873 | Howes | Apr 1985 | E |
| 4573481 | Bullara | Mar 1986 | A |
| 4586923 | Gould et al. | May 1986 | A |
| 4587975 | Salo et al. | May 1986 | A |
| 4643201 | Stokes | Feb 1987 | A |
| 4674518 | Salo | Jun 1987 | A |
| 4681117 | Brodman et al. | Jul 1987 | A |
| 4683890 | Hewson | Aug 1987 | A |
| 4697595 | Breyer et al. | Oct 1987 | A |
| 4706681 | Breyer et al. | Nov 1987 | A |
| 4771788 | Millar | Sep 1988 | A |
| 4819662 | Heil, Jr. et al. | Apr 1989 | A |
| 4827935 | Geddes et al. | May 1989 | A |
| 4830008 | Meer | May 1989 | A |
| 4840182 | Carlson | Jun 1989 | A |
| 4852580 | Wood | Aug 1989 | A |
| 4860769 | Fogarty et al. | Aug 1989 | A |
| 4905698 | Strohl, Jr. et al. | Mar 1990 | A |
| 4911174 | Pederson et al. | Mar 1990 | A |
| 4934049 | Kiekhafer et al. | Jun 1990 | A |
| 4944088 | Doan et al. | Jul 1990 | A |
| 4951682 | Petre | Aug 1990 | A |
| 4957110 | Vogel et al. | Sep 1990 | A |
| 4989617 | Memberg et al. | Feb 1991 | A |
| 5005587 | Scott | Apr 1991 | A |
| 5036848 | Hewson | Aug 1991 | A |
| 5042143 | Holleman et al. | Aug 1991 | A |
| 5056519 | Vince | Oct 1991 | A |
| 5115818 | Holleman et al. | May 1992 | A |
| 5146918 | Kallok et al. | Sep 1992 | A |
| 5170802 | Mehra | Dec 1992 | A |
| 5184621 | Vogel et al. | Feb 1993 | A |
| 5224491 | Mehra | Jul 1993 | A |
| 5243995 | Maier | Sep 1993 | A |
| 5265604 | Vince | Nov 1993 | A |
| 5267569 | Lienhard | Dec 1993 | A |
| 5314463 | Camps et al. | May 1994 | A |
| 5316009 | Yamada | May 1994 | A |
| 5324322 | Grill, Jr. et al. | Jun 1994 | A |
| 5330522 | Kreyenhagen | Jul 1994 | A |
| 5335657 | Terry, Jr. et al. | Aug 1994 | A |
| 5345936 | Pomeranz et al. | Sep 1994 | A |
| 5383923 | Webster, Jr. | Jan 1995 | A |
| 5397338 | Grey | Mar 1995 | A |
| 5411025 | Webster, Jr. | May 1995 | A |
| 5417208 | Winkler | May 1995 | A |
| 5451206 | Young | Sep 1995 | A |
| 5456254 | Pietroski et al. | Oct 1995 | A |
| 5465717 | Imran et al. | Nov 1995 | A |
| 5476498 | Ayers | Dec 1995 | A |
| 5486159 | Mahurkar | Jan 1996 | A |
| 5507725 | Savage et al. | Apr 1996 | A |
| 5524632 | Stein et al. | Jun 1996 | A |
| 5527358 | Mehmanesh et al. | Jun 1996 | A |
| 5531686 | Lundquist et al. | Jul 1996 | A |
| 5549655 | Erickson | Aug 1996 | A |
| 5555618 | Winkler | Sep 1996 | A |
| 5567724 | Kelleher et al. | Oct 1996 | A |
| 5584873 | Shoberg et al. | Dec 1996 | A |
| 5604231 | Smith et al. | Feb 1997 | A |
| 5665103 | Lafontaine et al. | Sep 1997 | A |
| 5678535 | Dimarco | Oct 1997 | A |
| 5683370 | Luther et al. | Nov 1997 | A |
| 5709853 | Iino et al. | Jan 1998 | A |
| 5716392 | Bourgeois et al. | Feb 1998 | A |
| 5733255 | Dinh et al. | Mar 1998 | A |
| 5755765 | Hyde et al. | May 1998 | A |
| 5776111 | Tesio | Jul 1998 | A |
| 5779732 | Amundson | Jul 1998 | A |
| 5782828 | Chen et al. | Jul 1998 | A |
| 5785706 | Bednarek | Jul 1998 | A |
| 5788681 | Weaver et al. | Aug 1998 | A |
| 5813399 | Isaza et al. | Sep 1998 | A |
| 5814086 | Hirschberg et al. | Sep 1998 | A |
| RE35924 | Winkler | Oct 1998 | E |
| 5824027 | Hoffer et al. | Oct 1998 | A |
| 5827192 | Gopakumaran et al. | Oct 1998 | A |
| 5916163 | Panescu et al. | Jun 1999 | A |
| 5944022 | Nardella et al. | Aug 1999 | A |
| 5954761 | Machek et al. | Sep 1999 | A |
| 5967978 | Littmann et al. | Oct 1999 | A |
| 5971933 | Gopakumaran et al. | Oct 1999 | A |
| 5983126 | Wittkampf | Nov 1999 | A |
| 6006134 | Hill et al. | Dec 1999 | A |
| 6024702 | Iversen | Feb 2000 | A |
| 6096728 | Collins et al. | Aug 2000 | A |
| 6120476 | Fung et al. | Sep 2000 | A |
| 6123699 | Webster, Jr. | Sep 2000 | A |
| 6126649 | Vantassel et al. | Oct 2000 | A |
| 6136021 | Tockman et al. | Oct 2000 | A |
| 6157862 | Brownlee et al. | Dec 2000 | A |
| 6161029 | Spreigl et al. | Dec 2000 | A |
| 6165133 | Rapoport | Dec 2000 | A |
| 6166048 | Bencherif | Dec 2000 | A |
| 6171277 | Ponzi | Jan 2001 | B1 |
| 6183463 | Webster, Jr. | Feb 2001 | B1 |
| 6198970 | Freed et al. | Mar 2001 | B1 |
| 6198974 | Webster, Jr. | Mar 2001 | B1 |
| 6201994 | Warman et al. | Mar 2001 | B1 |
| 6208881 | Champeau | Mar 2001 | B1 |
| 6210339 | Kiepen et al. | Apr 2001 | B1 |
| 6212435 | Lattner et al. | Apr 2001 | B1 |
| 6216045 | Black et al. | Apr 2001 | B1 |
| 6236892 | Feler | May 2001 | B1 |
| 6240320 | Spehr et al. | May 2001 | B1 |
| 6249708 | Nelson et al. | Jun 2001 | B1 |
| 6251126 | Ottenhoff et al. | Jun 2001 | B1 |
| 6269269 | Ottenhoff et al. | Jul 2001 | B1 |
| 6292695 | Webster, Jr. et al. | Sep 2001 | B1 |
| 6295475 | Morgan | Sep 2001 | B1 |
| 6360740 | Ward et al. | Mar 2002 | B1 |
| 6397108 | Camps et al. | May 2002 | B1 |
| 6400976 | Champeau | Jun 2002 | B1 |
| 6415183 | Scheiner et al. | Jul 2002 | B1 |
| 6415187 | Kuzma et al. | Jul 2002 | B1 |
| 6438427 | Rexhausen et al. | Aug 2002 | B1 |
| 6445953 | Bulkes et al. | Sep 2002 | B1 |
| 6449507 | Hill et al. | Sep 2002 | B1 |
| 6463327 | Lurie et al. | Oct 2002 | B1 |
| 6493590 | Wessman et al. | Dec 2002 | B1 |
| 6508802 | Rosengart et al. | Jan 2003 | B1 |
| 6526321 | Spehr | Feb 2003 | B1 |
| 6569114 | Ponzi et al. | May 2003 | B2 |
| 6584362 | Scheiner et al. | Jun 2003 | B1 |
| 6585718 | Hayzelden et al. | Jul 2003 | B2 |
| 6587726 | Lurie et al. | Jul 2003 | B2 |
| 6602242 | Fung et al. | Aug 2003 | B1 |
| 6610713 | Tracey | Aug 2003 | B2 |
| 6615085 | Boveja | Sep 2003 | B1 |
| 6630611 | Malowaniec | Oct 2003 | B1 |
| 6643552 | Edell et al. | Nov 2003 | B2 |
| 6651652 | Waard | Nov 2003 | B1 |
| 6682526 | Jones et al. | Jan 2004 | B1 |
| 6702780 | Gilboa et al. | Mar 2004 | B1 |
| 6718208 | Hill et al. | Apr 2004 | B2 |
| 6721603 | Zabara et al. | Apr 2004 | B2 |
| 6757970 | Kuzma et al. | Jul 2004 | B1 |
| 6778854 | Puskas | Aug 2004 | B2 |
| 6779257 | Kiepen et al. | Aug 2004 | B2 |
| 6844713 | Steber et al. | Jan 2005 | B2 |
| RE38705 | Hill et al. | Feb 2005 | E |
| 6881211 | Schweikert et al. | Apr 2005 | B2 |
| 6885888 | Rezai | Apr 2005 | B2 |
| 6907285 | Denker et al. | Jun 2005 | B2 |
| 6934583 | Weinberg et al. | Aug 2005 | B2 |
| 6981314 | Black et al. | Jan 2006 | B2 |
| 6999820 | Jordan | Feb 2006 | B2 |
| 7018374 | Schon et al. | Mar 2006 | B2 |
| 7047627 | Black et al. | May 2006 | B2 |
| 7071194 | Teng | Jul 2006 | B2 |
| 7072720 | Puskas | Jul 2006 | B2 |
| 7077823 | McDaniel | Jul 2006 | B2 |
| 7080645 | Genger et al. | Jul 2006 | B2 |
| 7082331 | Park et al. | Jul 2006 | B1 |
| 7130700 | Gardeski et al. | Oct 2006 | B2 |
| 7142903 | Rodriguez et al. | Nov 2006 | B2 |
| 7149585 | Wessman et al. | Dec 2006 | B2 |
| 7155278 | King et al. | Dec 2006 | B2 |
| 7167751 | Whitehurst et al. | Jan 2007 | B1 |
| 7168429 | Matthews et al. | Jan 2007 | B2 |
| 7184829 | Hill et al. | Feb 2007 | B2 |
| 7206636 | Turcott | Apr 2007 | B1 |
| 7212867 | Van Venrooij et al. | May 2007 | B2 |
| 7225016 | Koh | May 2007 | B1 |
| 7225019 | Jahns et al. | May 2007 | B2 |
| 7229429 | Martin et al. | Jun 2007 | B2 |
| 7231260 | Wallace et al. | Jun 2007 | B2 |
| 7235070 | Vanney | Jun 2007 | B2 |
| 7269459 | Koh | Sep 2007 | B1 |
| 7277757 | Casavant et al. | Oct 2007 | B2 |
| 7283875 | Larsson et al. | Oct 2007 | B2 |
| 7340302 | Falkenberg et al. | Mar 2008 | B1 |
| 7363085 | Benser et al. | Apr 2008 | B1 |
| 7363086 | Koh et al. | Apr 2008 | B1 |
| 7371220 | Koh et al. | May 2008 | B1 |
| 7416552 | Paul et al. | Aug 2008 | B2 |
| 7421296 | Benser et al. | Sep 2008 | B1 |
| 7454244 | Kassab et al. | Nov 2008 | B2 |
| 7519425 | Benser et al. | Apr 2009 | B2 |
| 7519426 | Koh et al. | Apr 2009 | B1 |
| 7522953 | Gharib et al. | Apr 2009 | B2 |
| 7553305 | Honebrink et al. | Jun 2009 | B2 |
| 7555349 | Wessman et al. | Jun 2009 | B2 |
| 7569029 | Clark et al. | Aug 2009 | B2 |
| 7591265 | Lee et al. | Sep 2009 | B2 |
| 7593760 | Rodriguez et al. | Sep 2009 | B2 |
| 7613524 | Jordan | Nov 2009 | B2 |
| 7636600 | Koh | Dec 2009 | B1 |
| 7670284 | Padget et al. | Mar 2010 | B2 |
| 7672728 | Libbus et al. | Mar 2010 | B2 |
| 7672729 | Koh et al. | Mar 2010 | B2 |
| 7676275 | Farazi et al. | Mar 2010 | B1 |
| 7676910 | Kiepen et al. | Mar 2010 | B2 |
| 7697984 | Hill et al. | Apr 2010 | B2 |
| 7747323 | Libbus et al. | Jun 2010 | B2 |
| 7771388 | Olsen et al. | Aug 2010 | B2 |
| 7783362 | Whitehurst et al. | Aug 2010 | B2 |
| 7794407 | Rothenberg | Sep 2010 | B2 |
| 7797050 | Libbus et al. | Sep 2010 | B2 |
| 7813805 | Farazi | Oct 2010 | B1 |
| 7819883 | Westlund et al. | Oct 2010 | B2 |
| 7840270 | Ignagni et al. | Nov 2010 | B2 |
| 7853302 | Rodriguez et al. | Dec 2010 | B2 |
| 7869865 | Govari et al. | Jan 2011 | B2 |
| 7891085 | Kuzma et al. | Feb 2011 | B1 |
| 7925352 | Stack et al. | Apr 2011 | B2 |
| 7949409 | Bly et al. | May 2011 | B2 |
| 7949412 | Harrison et al. | May 2011 | B1 |
| 7962215 | Ignagni et al. | Jun 2011 | B2 |
| 7970475 | Tehrani et al. | Jun 2011 | B2 |
| 7972323 | Bencini et al. | Jul 2011 | B1 |
| 7974693 | David et al. | Jul 2011 | B2 |
| 7974705 | Zdeblick et al. | Jul 2011 | B2 |
| 7979128 | Tehrani et al. | Jul 2011 | B2 |
| 7994655 | Bauer et al. | Aug 2011 | B2 |
| 8000765 | Rodriguez et al. | Aug 2011 | B2 |
| 8019439 | Kuzma et al. | Sep 2011 | B2 |
| 8021327 | Selkee | Sep 2011 | B2 |
| 8036750 | Caparso et al. | Oct 2011 | B2 |
| 8050765 | Lee et al. | Nov 2011 | B2 |
| 8052607 | Byrd | Nov 2011 | B2 |
| 8104470 | Lee et al. | Jan 2012 | B2 |
| 8116872 | Tehrani et al. | Feb 2012 | B2 |
| 8121692 | Haefner et al. | Feb 2012 | B2 |
| 8135471 | Zhang et al. | Mar 2012 | B2 |
| 8140164 | Tehrani et al. | Mar 2012 | B2 |
| 8147486 | Honour et al. | Apr 2012 | B2 |
| 8160701 | Zhao et al. | Apr 2012 | B2 |
| 8160711 | Tehrani et al. | Apr 2012 | B2 |
| 8195297 | Penner | Jun 2012 | B2 |
| 8200336 | Tehrani et al. | Jun 2012 | B2 |
| 8206343 | Racz | Jun 2012 | B2 |
| 8224456 | Daglow et al. | Jul 2012 | B2 |
| 8233987 | Gelfand et al. | Jul 2012 | B2 |
| 8233993 | Jordan | Jul 2012 | B2 |
| 8239037 | Glenn et al. | Aug 2012 | B2 |
| 8244358 | Tehrani et al. | Aug 2012 | B2 |
| 8244359 | Gelfand et al. | Aug 2012 | B2 |
| 8244378 | Bly et al. | Aug 2012 | B2 |
| 8255056 | Tehrani | Aug 2012 | B2 |
| 8256419 | Sinderby et al. | Sep 2012 | B2 |
| 8265736 | Sathaye et al. | Sep 2012 | B2 |
| 8265759 | Tehrani et al. | Sep 2012 | B2 |
| 8275440 | Rodriguez et al. | Sep 2012 | B2 |
| 8280513 | Tehrani et al. | Oct 2012 | B2 |
| 8315713 | Burnes et al. | Nov 2012 | B2 |
| 8321808 | Goetz et al. | Nov 2012 | B2 |
| 8335567 | Tehrani et al. | Dec 2012 | B2 |
| 8340783 | Sommer et al. | Dec 2012 | B2 |
| 8348941 | Tehrani | Jan 2013 | B2 |
| 8369954 | Stack et al. | Feb 2013 | B2 |
| 8374704 | Desai et al. | Feb 2013 | B2 |
| 8388541 | Messerly et al. | Mar 2013 | B2 |
| 8388546 | Rothenberg | Mar 2013 | B2 |
| 8391956 | Zellers et al. | Mar 2013 | B2 |
| 8401640 | Zhao et al. | Mar 2013 | B2 |
| 8401651 | Caparso et al. | Mar 2013 | B2 |
| 8406883 | Barker | Mar 2013 | B1 |
| 8406885 | Ignagni et al. | Mar 2013 | B2 |
| 8412331 | Tehrani et al. | Apr 2013 | B2 |
| 8412350 | Bly | Apr 2013 | B2 |
| 8428711 | Lin et al. | Apr 2013 | B2 |
| 8428726 | Ignagni et al. | Apr 2013 | B2 |
| 8428730 | Stack et al. | Apr 2013 | B2 |
| 8433412 | Westlund et al. | Apr 2013 | B1 |
| 8442638 | Libbus et al. | May 2013 | B2 |
| 8457764 | Ramachandran et al. | Jun 2013 | B2 |
| 8467876 | Tehrani | Jun 2013 | B2 |
| 8473068 | Farazi | Jun 2013 | B2 |
| 8478412 | Ignagni et al. | Jul 2013 | B2 |
| 8478413 | Karamanoglu et al. | Jul 2013 | B2 |
| 8478426 | Barker | Jul 2013 | B2 |
| 8483834 | Lee et al. | Jul 2013 | B2 |
| 8504158 | Karamanoglu et al. | Aug 2013 | B2 |
| 8504161 | Kornet et al. | Aug 2013 | B1 |
| 8509901 | Tehrani | Aug 2013 | B2 |
| 8509902 | Cho et al. | Aug 2013 | B2 |
| 8509919 | Yoo et al. | Aug 2013 | B2 |
| 8511303 | Djupesland | Aug 2013 | B2 |
| 8512256 | Rothenberg | Aug 2013 | B2 |
| 8522779 | Lee et al. | Sep 2013 | B2 |
| 8527036 | Jalde et al. | Sep 2013 | B2 |
| 8532793 | Morris et al. | Sep 2013 | B2 |
| 8554323 | Haefner et al. | Oct 2013 | B2 |
| 8560072 | Caparso et al. | Oct 2013 | B2 |
| 8560086 | Just et al. | Oct 2013 | B2 |
| 8571662 | Hoffer | Oct 2013 | B2 |
| 8571685 | Daglow et al. | Oct 2013 | B2 |
| 8615297 | Sathaye et al. | Dec 2013 | B2 |
| 8617228 | Wittenberger et al. | Dec 2013 | B2 |
| 8620412 | Griffiths et al. | Dec 2013 | B2 |
| 8620450 | Tockman et al. | Dec 2013 | B2 |
| 8626292 | McCabe et al. | Jan 2014 | B2 |
| 8630707 | Zhao et al. | Jan 2014 | B2 |
| 8644939 | Wilson et al. | Feb 2014 | B2 |
| 8644952 | Desai et al. | Feb 2014 | B2 |
| 8646172 | Kuzma et al. | Feb 2014 | B2 |
| 8650747 | Kuzma et al. | Feb 2014 | B2 |
| 8676323 | Ignagni et al. | Mar 2014 | B2 |
| 8676344 | Desai et al. | Mar 2014 | B2 |
| 8694123 | Wahlstrand et al. | Apr 2014 | B2 |
| 8696656 | Abboud et al. | Apr 2014 | B2 |
| 8706223 | Zhou et al. | Apr 2014 | B2 |
| 8706235 | Karamanoglu et al. | Apr 2014 | B2 |
| 8706236 | Ignagni et al. | Apr 2014 | B2 |
| 8718763 | Zhou et al. | May 2014 | B2 |
| 8725259 | Kornet et al. | May 2014 | B2 |
| 8738154 | Zdeblick et al. | May 2014 | B2 |
| 8755889 | Scheiner | Jun 2014 | B2 |
| 8774907 | Rothenberg | Jul 2014 | B2 |
| 8781578 | McCabe et al. | Jul 2014 | B2 |
| 8781582 | Ziegler et al. | Jul 2014 | B2 |
| 8781583 | Cornelussen et al. | Jul 2014 | B2 |
| 8801693 | He et al. | Aug 2014 | B2 |
| 8805511 | Karamanoglu et al. | Aug 2014 | B2 |
| 8838245 | Lin et al. | Sep 2014 | B2 |
| 8858455 | Rothenberg | Oct 2014 | B2 |
| 8863742 | Blomquist et al. | Oct 2014 | B2 |
| 8886277 | Kim et al. | Nov 2014 | B2 |
| 8897879 | Karamanoglu et al. | Nov 2014 | B2 |
| 8903507 | Desai et al. | Dec 2014 | B2 |
| 8903509 | Tockman et al. | Dec 2014 | B2 |
| 8909341 | Gelfand et al. | Dec 2014 | B2 |
| 8914113 | Zhang et al. | Dec 2014 | B2 |
| 8918169 | Kassab et al. | Dec 2014 | B2 |
| 8918987 | Kuzma et al. | Dec 2014 | B2 |
| 8923971 | Haefner et al. | Dec 2014 | B2 |
| 8942823 | Desai et al. | Jan 2015 | B2 |
| 8942824 | Yoo et al. | Jan 2015 | B2 |
| 8948884 | Ramachandran et al. | Feb 2015 | B2 |
| 8968299 | Kauphusman et al. | Mar 2015 | B2 |
| 8972015 | Stack et al. | Mar 2015 | B2 |
| 8983602 | Sathaye et al. | Mar 2015 | B2 |
| 9008775 | Sathaye et al. | Apr 2015 | B2 |
| 9026231 | Hoffer | May 2015 | B2 |
| 9037264 | Just et al. | May 2015 | B2 |
| 9042981 | Yoo et al. | May 2015 | B2 |
| 9072864 | Putz | Jul 2015 | B2 |
| 9072899 | Nickloes | Jul 2015 | B1 |
| 9108058 | Hoffer | Aug 2015 | B2 |
| 9108059 | Hoffer | Aug 2015 | B2 |
| 9125578 | Grunwald | Sep 2015 | B2 |
| 9138580 | Ignagni et al. | Sep 2015 | B2 |
| 9138585 | Saha et al. | Sep 2015 | B2 |
| 9149642 | McCabe et al. | Oct 2015 | B2 |
| 9168377 | Hoffer | Oct 2015 | B2 |
| 9174046 | Francois et al. | Nov 2015 | B2 |
| 9199075 | Westlund | Dec 2015 | B1 |
| 9205258 | Simon et al. | Dec 2015 | B2 |
| 9216291 | Lee et al. | Dec 2015 | B2 |
| 9220898 | Hoffer | Dec 2015 | B2 |
| 9226688 | Jacobsen et al. | Jan 2016 | B2 |
| 9226689 | Jacobsen et al. | Jan 2016 | B2 |
| 9242088 | Thakkar et al. | Jan 2016 | B2 |
| 9259573 | Tehrani et al. | Feb 2016 | B2 |
| 9295846 | Westlund et al. | Mar 2016 | B2 |
| 9314618 | Imran et al. | Apr 2016 | B2 |
| 9333363 | Hoffer et al. | May 2016 | B2 |
| 9345422 | Rothenberg | May 2016 | B2 |
| 9370657 | Tehrani et al. | Jun 2016 | B2 |
| 9398931 | Wittenberger et al. | Jul 2016 | B2 |
| 9415188 | He et al. | Aug 2016 | B2 |
| 9427566 | Reed et al. | Aug 2016 | B2 |
| 9427588 | Sathaye et al. | Aug 2016 | B2 |
| 9468755 | Westlund | Oct 2016 | B2 |
| 9474894 | Mercanzini et al. | Oct 2016 | B2 |
| 9485873 | Shah et al. | Nov 2016 | B2 |
| 9498625 | Bauer | Nov 2016 | B2 |
| 9498631 | Demmer et al. | Nov 2016 | B2 |
| 9504837 | Demmer et al. | Nov 2016 | B2 |
| 9532724 | Grunwald et al. | Jan 2017 | B2 |
| 9533160 | Brooke et al. | Jan 2017 | B2 |
| 9539429 | Brooke et al. | Jan 2017 | B2 |
| 9545511 | Thakkar et al. | Jan 2017 | B2 |
| 9561369 | Burnes et al. | Feb 2017 | B2 |
| 9566436 | Hoffer et al. | Feb 2017 | B2 |
| 9572982 | Burnes et al. | Feb 2017 | B2 |
| 9597509 | Hoffer et al. | Mar 2017 | B2 |
| 9615759 | Hurezan et al. | Apr 2017 | B2 |
| 9623239 | Francois et al. | Apr 2017 | B2 |
| 9623252 | Sathaye et al. | Apr 2017 | B2 |
| 9662494 | Young et al. | May 2017 | B2 |
| 9682235 | O'Mahony et al. | Jun 2017 | B1 |
| 9694185 | Bauer | Jul 2017 | B2 |
| 9717899 | Kuzma et al. | Aug 2017 | B2 |
| 9724018 | Cho et al. | Aug 2017 | B2 |
| 9744349 | Westlund et al. | Aug 2017 | B2 |
| 9744351 | Gelfand et al. | Aug 2017 | B1 |
| 9776005 | Meyyappan et al. | Oct 2017 | B2 |
| 9861817 | Cho et al. | Jan 2018 | B2 |
| 9872989 | Jung et al. | Jan 2018 | B2 |
| 9884178 | Bouton et al. | Feb 2018 | B2 |
| 9884179 | Bouton et al. | Feb 2018 | B2 |
| 9919149 | Imran et al. | Mar 2018 | B2 |
| 9931504 | Thakkar et al. | Apr 2018 | B2 |
| 9950167 | Hoffer et al. | Apr 2018 | B2 |
| 9956132 | Francois et al. | May 2018 | B2 |
| 9956396 | Young et al. | May 2018 | B2 |
| 9968785 | Hoffer et al. | May 2018 | B2 |
| 9968786 | Bauer | May 2018 | B2 |
| 9987488 | Gelfand et al. | Jun 2018 | B1 |
| 9999768 | Gelfand et al. | Jun 2018 | B2 |
| 10022546 | Hoffer et al. | Jul 2018 | B2 |
| 10035017 | Thakkar et al. | Jul 2018 | B2 |
| 10039920 | Thakkar et al. | Aug 2018 | B1 |
| 10195429 | Thakkar et al. | Feb 2019 | B1 |
| 10293164 | Nash et al. | May 2019 | B2 |
| 10300270 | Gelfand et al. | May 2019 | B2 |
| 10315035 | Bauer | Jun 2019 | B2 |
| 10335592 | Bauer et al. | Jul 2019 | B2 |
| 10369361 | Bauer et al. | Aug 2019 | B2 |
| 10391314 | Hoffer et al. | Aug 2019 | B2 |
| 10406366 | Westlund et al. | Sep 2019 | B2 |
| 10406367 | Meyyappan | Sep 2019 | B2 |
| 10413203 | Saha et al. | Sep 2019 | B2 |
| 10448995 | Olson | Oct 2019 | B2 |
| 10493271 | Bauer | Dec 2019 | B2 |
| 20010052345 | Niazi | Dec 2001 | A1 |
| 20020026228 | Schauerte | Feb 2002 | A1 |
| 20020056454 | Samzelius | May 2002 | A1 |
| 20020065544 | Smits et al. | May 2002 | A1 |
| 20020087156 | Maguire et al. | Jul 2002 | A1 |
| 20020128546 | Silver | Sep 2002 | A1 |
| 20020188325 | Hill et al. | Dec 2002 | A1 |
| 20030078623 | Weinberg et al. | Apr 2003 | A1 |
| 20030195571 | Burnes et al. | Oct 2003 | A1 |
| 20040003813 | Banner et al. | Jan 2004 | A1 |
| 20040010303 | Bolea et al. | Jan 2004 | A1 |
| 20040030362 | Hill et al. | Feb 2004 | A1 |
| 20040044377 | Larsson et al. | Mar 2004 | A1 |
| 20040064069 | Reynolds et al. | Apr 2004 | A1 |
| 20040077936 | Larsson et al. | Apr 2004 | A1 |
| 20040088015 | Casavant et al. | May 2004 | A1 |
| 20040111139 | McCreery | Jun 2004 | A1 |
| 20040172075 | Shafer et al. | Sep 2004 | A1 |
| 20040186543 | King et al. | Sep 2004 | A1 |
| 20040210261 | King et al. | Oct 2004 | A1 |
| 20040254612 | Ezra | Dec 2004 | A1 |
| 20050004565 | Vanney | Jan 2005 | A1 |
| 20050013879 | Lin et al. | Jan 2005 | A1 |
| 20050021102 | Ignagni et al. | Jan 2005 | A1 |
| 20050027338 | Hill | Feb 2005 | A1 |
| 20050033136 | Govari et al. | Feb 2005 | A1 |
| 20050033137 | Oral et al. | Feb 2005 | A1 |
| 20050043765 | Williams et al. | Feb 2005 | A1 |
| 20050065567 | Lee et al. | Mar 2005 | A1 |
| 20050070981 | Verma | Mar 2005 | A1 |
| 20050075578 | Gharib et al. | Apr 2005 | A1 |
| 20050085865 | Tehrani | Apr 2005 | A1 |
| 20050085866 | Tehrani | Apr 2005 | A1 |
| 20050085867 | Tehrani et al. | Apr 2005 | A1 |
| 20050085868 | Tehrani et al. | Apr 2005 | A1 |
| 20050085869 | Tehrani et al. | Apr 2005 | A1 |
| 20050096710 | Kieval | May 2005 | A1 |
| 20050109340 | Tehrani | May 2005 | A1 |
| 20050113710 | Stahmann et al. | May 2005 | A1 |
| 20050115561 | Stahmann et al. | Jun 2005 | A1 |
| 20050131485 | Knudson et al. | Jun 2005 | A1 |
| 20050138791 | Black et al. | Jun 2005 | A1 |
| 20050138792 | Black et al. | Jun 2005 | A1 |
| 20050143787 | Boveja et al. | Jun 2005 | A1 |
| 20050165457 | Benser et al. | Jul 2005 | A1 |
| 20050182454 | Gharib et al. | Aug 2005 | A1 |
| 20050187584 | Denker et al. | Aug 2005 | A1 |
| 20050192655 | Black et al. | Sep 2005 | A1 |
| 20050251238 | Wallace et al. | Nov 2005 | A1 |
| 20050251239 | Wallace et al. | Nov 2005 | A1 |
| 20050288728 | Libbus | Dec 2005 | A1 |
| 20050288730 | Deem et al. | Dec 2005 | A1 |
| 20060030894 | Tehrani | Feb 2006 | A1 |
| 20060035849 | Spiegelman et al. | Feb 2006 | A1 |
| 20060058852 | Koh et al. | Mar 2006 | A1 |
| 20060074449 | Denker et al. | Apr 2006 | A1 |
| 20060079936 | Boveja | Apr 2006 | A1 |
| 20060122661 | Mandell | Jun 2006 | A1 |
| 20060122662 | Tehrani et al. | Jun 2006 | A1 |
| 20060130833 | Younes | Jun 2006 | A1 |
| 20060142815 | Tehrani et al. | Jun 2006 | A1 |
| 20060149334 | Tehrani et al. | Jul 2006 | A1 |
| 20060155222 | Sherman et al. | Jul 2006 | A1 |
| 20060167523 | Tehrani et al. | Jul 2006 | A1 |
| 20060188325 | Dolan | Aug 2006 | A1 |
| 20060195159 | Bradley et al. | Aug 2006 | A1 |
| 20060217791 | Spinka et al. | Sep 2006 | A1 |
| 20060024222 | Bradley et al. | Oct 2006 | A1 |
| 20060224209 | Meyer | Oct 2006 | A1 |
| 20060229677 | Moffitt et al. | Oct 2006 | A1 |
| 20060247729 | Tehrani et al. | Nov 2006 | A1 |
| 20060253161 | Libbus et al. | Nov 2006 | A1 |
| 20060253182 | King | Nov 2006 | A1 |
| 20060258667 | Teng | Nov 2006 | A1 |
| 20060259107 | Caparso et al. | Nov 2006 | A1 |
| 20060282131 | Caparso et al. | Dec 2006 | A1 |
| 20060287679 | Stone | Dec 2006 | A1 |
| 20070005053 | Dando | Jan 2007 | A1 |
| 20070021795 | Tehrani | Jan 2007 | A1 |
| 20070027448 | Paul et al. | Feb 2007 | A1 |
| 20070043400 | Donders | Feb 2007 | A1 |
| 20070087314 | Gomo | Apr 2007 | A1 |
| 20070093875 | Chavan et al. | Apr 2007 | A1 |
| 20070106339 | Errico | May 2007 | A1 |
| 20070106357 | Denker et al. | May 2007 | A1 |
| 20070112402 | Grill et al. | May 2007 | A1 |
| 20070112403 | Moffitt et al. | May 2007 | A1 |
| 20070118183 | Gelfand et al. | May 2007 | A1 |
| 20070150006 | Libbus et al. | Jun 2007 | A1 |
| 20070150026 | Bourget | Jun 2007 | A1 |
| 20070168007 | Kuzma et al. | Jul 2007 | A1 |
| 20070173900 | Siegel et al. | Jul 2007 | A1 |
| 20070191908 | Jacob et al. | Aug 2007 | A1 |
| 20070196780 | Ware et al. | Aug 2007 | A1 |
| 20070203549 | Demarais et al. | Aug 2007 | A1 |
| 20070208388 | Jahns et al. | Sep 2007 | A1 |
| 20070221224 | Pittman et al. | Sep 2007 | A1 |
| 20070240718 | Daly | Oct 2007 | A1 |
| 20070250056 | Vanney | Oct 2007 | A1 |
| 20070250162 | Royalty | Oct 2007 | A1 |
| 20070255379 | Williams et al. | Nov 2007 | A1 |
| 20070265611 | Ignagni et al. | Nov 2007 | A1 |
| 20070277832 | Doshi | Dec 2007 | A1 |
| 20070288076 | Bulkes et al. | Dec 2007 | A1 |
| 20080039916 | Colliou et al. | Feb 2008 | A1 |
| 20080065002 | Lobl et al. | Mar 2008 | A1 |
| 20080125828 | Ignagni | May 2008 | A1 |
| 20080161878 | Tehrani et al. | Jul 2008 | A1 |
| 20080167695 | Tehrani et al. | Jul 2008 | A1 |
| 20080177190 | Libbus | Jul 2008 | A1 |
| 20080177347 | Tehrani et al. | Jul 2008 | A1 |
| 20080183186 | Bly et al. | Jul 2008 | A1 |
| 20080183187 | Bly | Jul 2008 | A1 |
| 20080183239 | Tehrani et al. | Jul 2008 | A1 |
| 20080183240 | Tehrani et al. | Jul 2008 | A1 |
| 20080183253 | Bly | Jul 2008 | A1 |
| 20080183254 | Bly et al. | Jul 2008 | A1 |
| 20080183255 | Bly et al. | Jul 2008 | A1 |
| 20080183259 | Bly et al. | Jul 2008 | A1 |
| 20080183264 | Bly et al. | Jul 2008 | A1 |
| 20080183265 | Bly et al. | Jul 2008 | A1 |
| 20080188903 | Tehrani et al. | Aug 2008 | A1 |
| 20080215106 | Lee et al. | Sep 2008 | A1 |
| 20080243007 | Liao | Oct 2008 | A1 |
| 20080288010 | Tehrani et al. | Nov 2008 | A1 |
| 20080288015 | Tehrani et al. | Nov 2008 | A1 |
| 20080312712 | Penner | Dec 2008 | A1 |
| 20080312725 | Penner | Dec 2008 | A1 |
| 20090024047 | Shipley et al. | Jan 2009 | A1 |
| 20090024176 | Yun et al. | Jan 2009 | A1 |
| 20090036947 | Westlund et al. | Feb 2009 | A1 |
| 20090118785 | Ignagni et al. | May 2009 | A1 |
| 20090275956 | Burnes et al. | Nov 2009 | A1 |
| 20090275996 | Burnes et al. | Nov 2009 | A1 |
| 20090276022 | Burnes et al. | Nov 2009 | A1 |
| 20090318993 | Eidenschink et al. | Dec 2009 | A1 |
| 20100022950 | Anderson et al. | Jan 2010 | A1 |
| 20100036451 | Hoffer | Feb 2010 | A1 |
| 20100057046 | Stevens | Mar 2010 | A1 |
| 20100077606 | Black et al. | Apr 2010 | A1 |
| 20100094376 | Penner | Apr 2010 | A1 |
| 20100105977 | De Taboada et al. | Apr 2010 | A1 |
| 20100114227 | Cholette | May 2010 | A1 |
| 20100114254 | Kornet | May 2010 | A1 |
| 20100198296 | Ignagni et al. | Aug 2010 | A1 |
| 20100204766 | Zdeblick et al. | Aug 2010 | A1 |
| 20100268311 | Cardinal et al. | Oct 2010 | A1 |
| 20100319691 | Lurie et al. | Dec 2010 | A1 |
| 20110046432 | Simon | Feb 2011 | A1 |
| 20110060381 | Ignagni et al. | Mar 2011 | A1 |
| 20110077726 | Westlund et al. | Mar 2011 | A1 |
| 20110087301 | Li et al. | Apr 2011 | A1 |
| 20110093032 | Boggs, II et al. | Apr 2011 | A1 |
| 20110118815 | Kuzma et al. | May 2011 | A1 |
| 20110152967 | Bruce et al. | Jun 2011 | A1 |
| 20110224750 | Scheiner | Sep 2011 | A1 |
| 20110230932 | Tehrani et al. | Sep 2011 | A1 |
| 20110230935 | Zdeblick | Sep 2011 | A1 |
| 20110230945 | Ohtaka et al. | Sep 2011 | A1 |
| 20110270358 | Davis et al. | Nov 2011 | A1 |
| 20110288609 | Tehrani et al. | Nov 2011 | A1 |
| 20120035684 | Thompson et al. | Feb 2012 | A1 |
| 20120053654 | Tehrani et al. | Mar 2012 | A1 |
| 20120078320 | Schotzko et al. | Mar 2012 | A1 |
| 20120130217 | Kauphusman et al. | May 2012 | A1 |
| 20120158091 | Tehrani et al. | Jun 2012 | A1 |
| 20120209284 | Westlund et al. | Aug 2012 | A1 |
| 20120215278 | Penner | Aug 2012 | A1 |
| 20120323293 | Tehrani et al. | Dec 2012 | A1 |
| 20130018247 | Glenn et al. | Jan 2013 | A1 |
| 20130018427 | Pham et al. | Jan 2013 | A1 |
| 20130023972 | Kuzma et al. | Jan 2013 | A1 |
| 20130030496 | Karamanoglu et al. | Jan 2013 | A1 |
| 20130030497 | Karamanoglu et al. | Jan 2013 | A1 |
| 20130030498 | Karamanoglu et al. | Jan 2013 | A1 |
| 20130060245 | Grunewald et al. | Mar 2013 | A1 |
| 20130066392 | Bruce et al. | Mar 2013 | A1 |
| 20130116743 | Karamanoglu et al. | May 2013 | A1 |
| 20130123891 | Swanson | May 2013 | A1 |
| 20130131743 | Yamasaki et al. | May 2013 | A1 |
| 20130158625 | Gelfand et al. | Jun 2013 | A1 |
| 20130165989 | Gelfand et al. | Jun 2013 | A1 |
| 20130167372 | Black et al. | Jul 2013 | A1 |
| 20130197601 | Tehrani et al. | Aug 2013 | A1 |
| 20130237906 | Park et al. | Sep 2013 | A1 |
| 20130268018 | Brooke et al. | Oct 2013 | A1 |
| 20130289686 | Masson et al. | Oct 2013 | A1 |
| 20130296964 | Tehrani | Nov 2013 | A1 |
| 20130296973 | Tehrani et al. | Nov 2013 | A1 |
| 20130317587 | Barker | Nov 2013 | A1 |
| 20130333696 | Lee et al. | Dec 2013 | A1 |
| 20140067032 | Morris et al. | Mar 2014 | A1 |
| 20140088580 | Wittenberger et al. | Mar 2014 | A1 |
| 20140114371 | Westlund et al. | Apr 2014 | A1 |
| 20140121716 | Casavant et al. | May 2014 | A1 |
| 20140128953 | Zhao et al. | May 2014 | A1 |
| 20140148780 | Putz | May 2014 | A1 |
| 20140288551 | Rupinder et al. | Sep 2014 | A1 |
| 20140316486 | Zhou et al. | Oct 2014 | A1 |
| 20140324115 | Ziegler et al. | Oct 2014 | A1 |
| 20140378803 | Geistert et al. | Dec 2014 | A1 |
| 20150018839 | Morris et al. | Jan 2015 | A1 |
| 20150034081 | Tehrani et al. | Feb 2015 | A1 |
| 20150045810 | Hoffer et al. | Feb 2015 | A1 |
| 20150045848 | Cho et al. | Feb 2015 | A1 |
| 20150119950 | Demmer et al. | Apr 2015 | A1 |
| 20150142082 | Simon et al. | May 2015 | A1 |
| 20150165207 | Karamanoglu | Jun 2015 | A1 |
| 20150196354 | Haverkost et al. | Jul 2015 | A1 |
| 20150196356 | Kauphusman et al. | Jul 2015 | A1 |
| 20150202448 | Hoffer et al. | Jul 2015 | A1 |
| 20150231348 | Lee et al. | Aug 2015 | A1 |
| 20150250982 | Osypka et al. | Sep 2015 | A1 |
| 20150265833 | Meyyappan et al. | Sep 2015 | A1 |
| 20150283340 | Zhang et al. | Oct 2015 | A1 |
| 20150290476 | Krocak et al. | Oct 2015 | A1 |
| 20150359487 | Coulombe | Dec 2015 | A1 |
| 20150374252 | De La Rama et al. | Dec 2015 | A1 |
| 20150374991 | Morris et al. | Dec 2015 | A1 |
| 20160001072 | Gelfand et al. | Jan 2016 | A1 |
| 20160114165 | Levine et al. | Apr 2016 | A1 |
| 20160129244 | Westlund | May 2016 | A1 |
| 20160144078 | Young et al. | May 2016 | A1 |
| 20160193460 | Xu et al. | Jul 2016 | A1 |
| 20160228696 | Imran et al. | Aug 2016 | A1 |
| 20160239627 | Cerny et al. | Aug 2016 | A1 |
| 20160256692 | Baru | Sep 2016 | A1 |
| 20160310730 | Martins et al. | Oct 2016 | A1 |
| 20160331326 | Xiang et al. | Nov 2016 | A1 |
| 20160367815 | Hoffer | Dec 2016 | A1 |
| 20170007825 | Thakkar et al. | Jan 2017 | A1 |
| 20170013713 | Shah et al. | Jan 2017 | A1 |
| 20170021163 | Westlund et al. | Jan 2017 | A1 |
| 20170021166 | Bauer et al. | Jan 2017 | A1 |
| 20170028191 | Mercanzini et al. | Feb 2017 | A1 |
| 20170036017 | Tehrani et al. | Feb 2017 | A1 |
| 20170050033 | Wechter | Feb 2017 | A1 |
| 20170143973 | Tehrani | May 2017 | A1 |
| 20170143975 | Hoffer et al. | May 2017 | A1 |
| 20170196503 | Narayan et al. | Jul 2017 | A1 |
| 20170224993 | Sathaye et al. | Aug 2017 | A1 |
| 20170232250 | Kim et al. | Aug 2017 | A1 |
| 20170252558 | O'Mahony et al. | Sep 2017 | A1 |
| 20170291023 | Kuzma et al. | Oct 2017 | A1 |
| 20170296812 | O'Mahony et al. | Oct 2017 | A1 |
| 20170312006 | McFarlin et al. | Nov 2017 | A1 |
| 20170312507 | Bauer et al. | Nov 2017 | A1 |
| 20170312508 | Bauer et al. | Nov 2017 | A1 |
| 20170312509 | Bauer et al. | Nov 2017 | A1 |
| 20170326354 | Westlund et al. | Nov 2017 | A1 |
| 20170326359 | Gelfand et al. | Nov 2017 | A1 |
| 20170347921 | Haber et al. | Dec 2017 | A1 |
| 20180001086 | Bartholomew et al. | Jan 2018 | A1 |
| 20180008821 | Gonzalez et al. | Jan 2018 | A1 |
| 20180110562 | Govari et al. | Apr 2018 | A1 |
| 20180117334 | Jung | May 2018 | A1 |
| 20180256440 | Francois et al. | Sep 2018 | A1 |
| 20180280691 | Ackermann | Oct 2018 | A1 |
| 20180280692 | Gelfand et al. | Oct 2018 | A1 |
| 20180326209 | Gelfand et al. | Nov 2018 | A1 |
| 20190247656 | Bauer | Aug 2019 | A1 |
| 20190255322 | Bauer et al. | Aug 2019 | A1 |
| 20190351229 | Westlund et al. | Nov 2019 | A1 |
| 20200188659 | Evans | Jun 2020 | A1 |
| Number | Date | Country |
|---|---|---|
| 1652839 | Aug 2005 | CN |
| 102143781 | Aug 2011 | CN |
| 0993840 | Apr 2000 | EP |
| 1304135 | Apr 2003 | EP |
| 0605796 | Aug 2003 | EP |
| 1833558 | Sep 2007 | EP |
| 2489395 | Aug 2012 | EP |
| 2801509 | Jun 2001 | FR |
| H08510677 | Nov 1996 | JP |
| 2003503119 | Jan 2003 | JP |
| 2010516353 | May 2010 | JP |
| 2011200571 | Oct 2011 | JP |
| 2012000195 | Jan 2012 | JP |
| WO-9407564 | Apr 1994 | WO |
| WO-9508357 | Mar 1995 | WO |
| WO-9964105 | Dec 1999 | WO |
| WO-9965561 | Dec 1999 | WO |
| WO-0100273 | Jan 2001 | WO |
| WO-02058785 | Aug 2002 | WO |
| WO-03005887 | Jan 2003 | WO |
| WO-03094855 | Nov 2003 | WO |
| WO-2005018524 | Mar 2005 | WO |
| 2005053788 | Jun 2005 | WO |
| 2006066280 | Jun 2006 | WO |
| WO-2006063339 | Jun 2006 | WO |
| WO-2006110338 | Oct 2006 | WO |
| WO-2006115877 | Nov 2006 | WO |
| WO-2007053508 | May 2007 | WO |
| WO-2008092246 | Aug 2008 | WO |
| WO-2008094344 | Aug 2008 | WO |
| WO-2009006337 | Jan 2009 | WO |
| WO-2009134459 | Nov 2009 | WO |
| WO-2010029842 | Mar 2010 | WO |
| WO-2010148412 | Dec 2010 | WO |
| WO-2011094631 | Aug 2011 | WO |
| WO-2011158410 | Dec 2011 | WO |
| WO-2012106533 | Aug 2012 | WO |
| WO-2013131187 | Sep 2013 | WO |
| WO-2013188965 | Dec 2013 | WO |
| WO-2014008171 | Jan 2014 | WO |
| WO-2015075548 | May 2015 | WO |
| WO-2015109401 | Jul 2015 | WO |
| WO-2019154834 | Aug 2019 | WO |
| WO-2019154837 | Aug 2019 | WO |
| WO-2019154839 | Aug 2019 | WO |
| Entry |
|---|
| Antonica A., et al., “Vagal Control of Lymphocyte Release from Rat Thymus,” Journal of the Autonomic Nervous System, Elsevier, vol. 48(3), Aug. 1994, pp. 187-197. |
| Ayas N.T., et al., “Prevention of Human Diaphragm Atrophy with Short periods of Electrical Stimulation,” American Journal of Respiratory and Critical Care Medicine, Jun. 1999, vol. 159(6), pp. 2018-2020. |
| Borovikova, et al., “Role of the Vagus Nerve in the Anti-Inflammatory Effects of CNI-1493,” Proceedings of the Annual Meeting of Professional Research Scientists: Experimental Biology 2000, Abstract 97.9, Apr. 15-18, 2000. |
| Borovikova L.V., et al., “Role of Vagus Nerve Signaling in CNI-1493-Mediated Suppression of Acute Inflammation,” Autonomic Neuroscience: Basic and Clinical, vol. 85 (1-3), Dec. 20, 2000, pp. 141-147. |
| Borovikova L.V., et al., “Vagus Nerve Stimulation Attenuates the Systemic Inflammatory Response to Endotoxin,” Nature, Macmillan Magazines Ltd, vol. 405, May 25, 2000, pp. 458-462. |
| Chinese Search Report for Application No. CN2013/80023357.5, dated Jul. 24, 2015. |
| Co-pending U.S. Appl. No. 15/606,867, filed May 26, 2017. |
| Daggeti, W.M. et al., “Intracaval Electrophrenic Stimulation. I. Experimental Application during Barbiturate Intoxication Hemorrhage and Gang,” Journal of Thoracic and Cardiovascular Surgery, 1966, vol. 51 (5), pp. 676-884. |
| Daggeti, W.M. et al., “Intracaval electrophrenic stimulation. II. Studies on Pulmonary Mechanics Surface Tension Urine Flow and Bilateral Ph,” Journal of Thoracic and Cardiovascular Surgery, 1970, vol. 60(1 ), pp. 98-107. |
| De Gregorio, M.A. et al., “The Gunther Tulip Retrievable Filter: Prolonged Temporary Filtration by Repositioning within the Inferior Vena Cava,” Journal of Vascular and Interventional Radiology, 2003, vol. 14, pp. 1259-1265. |
| Deng Y-J et al., “The Effect of Positive Pressure Ventilation Combined with Diaphragm Pacing on Respiratory Mechanics in Patients with Respiratory Failure; Respiratory Mechanics,” Chinese critical care medicine, Apr. 2011, vol. 23(4), pp. 213-215. |
| Escher, Doris J.W. et al., “Clinical Control of Respiration by Transvenous Phrenic Pacing,” American Society for Artificial Internal Organs: Apr. 1968—vol. 14—Issue 1—pp. 192-197. |
| European Search Report for Application No. 13758363, dated Nov. 12, 2015. |
| European Search Report for Application No. EP17169051.4, dated Sep. 8, 2017, 7 pages. |
| Extended European Search Report for Application No. 14864542.7, dated Jun. 2, 2017, 8 pages. |
| Extended European Search Report for Application No. 15740415.3, dated Jul. 7, 2017. |
| Fleshner M., et al., “Thermogenic and Corticosterone Responses to Intravenous Cytokines (IL-1β and TNF-α) are Attenuated by Subdiaphragmatic Vagotomy,” Journal of Neuroimmunology, vol. 86, Jun. 1998, pp. 134-141. |
| Frisch S., “A Feasibility Study of a Novel Minimally Invasive Approach for Diaphragm Pacing,” Master of Science Thesis, Simon Fraser University, 2009, p. 148. |
| Furman, S., “Transvenous Stimulation of the Phrenic Nerves,” Journal of Thoracic and Cardiovascular Surgery, 1971, vol. 62 (5), pp. 743-751. |
| Gaykema R.P.A. et al., “Subdiaphragmatic Vagotomy Suppresses Endotoxin-Induced Activation of Hypothalamic Corticotropin-Releasing Hormone Neurons and ACTH Secretion,” Endocrinology, The Endocrine Society, vol. 136 (10), 1995, pp. 4717-4720. |
| Gupta A.K., “Respiration Rate Measurement Based on Impedance Pneumography,” Data Acquisition Products, Texas Instruments, Application Report, SBAA181, Feb. 2011, 11 pages. |
| Guslandi M., “Nicotine Treatment for Ulcerative Colitis,” The British Journal of Clinical Pharmacology, Blackwell Science Ltd, vol. 48, 1999, pp. 481-484. |
| Hoffer J.A. et al., “Diaphragm Pacing with Endovascular Electrodes”, IFESS 2010—International Functional Electrical Stimulation Society, 15th Anniversary Conference, Vienna, Austria, Sep. 2010. |
| Huffman, William J. et al., “Modulation of Neuroinflammation and Memory Dysfunction Using Percutaneous Vagus Nerve Stimulation in Mice,” Brain Stimulation, 2018. |
| Ishii, K. et al., “Effects of Bilateral Transvenous Diaphragm Pacing on Hemodynamic Function in Patients after Cardiac Operations,” J. Thorac. Cardiovasc. Surg., 1990. |
| Japanese Office Action in corresponding Japanese Application No. 2014-560202, dated Dec. 6, 2016, 4 pages. |
| Japanese Office Action in corresponding Japanese Application No. 2014-560202, dated Oct. 17, 2017, 5 pages. |
| Kawashima K., et al., “Extraneuronal Cholinergic System in Lymphocytes,” Pharmacology & Therapeutics, Elsevier, vol. 86, 2000, pp. 29-48. |
| Levine S., et al., “Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans,” New England Journal of Medicine, 2008, vol. 358, pp. 1327-1335. |
| Lungpacer: Therapy, News.< http://lungpacer.com>. Accessed Dec. 27, 2016. |
| Madretsma, G.S., et al., “Nicotine Inhibits the In-vitro Production of Interleukin 2 and Tumour Necrosis Factor-α by Human Mononuclear Cells,” Immunopharmacology, Elsevier, vol. 35 (1), Oct. 1996, pp. 47-51. |
| Marcy, T.W. et al., “Diaphragm Pacing for Ventilatory Insufficiency,” Journal of Intensive Care Medicine, 1987, vol. 2 (6), pp. 345-353. |
| Meyyappan R., “Diaphragm Pacing during Controlled Mechanical Ventilation: Pre-Clinical Observations Reveal A Substantial Improvement In Respiratory Mechanics”, 17th Biennial Canadian Biomechanics Society Meeting, Burnaby, BC, Jun. 6-9, 2012. |
| Nabutovsky, Y., et al., “Lead Design and Initial Applications of a New Lead for Long-Term Endovascular Vagal Stimulation,” PACE, Blackwell Publishing, Inc, vol. 30(1), Jan. 2007, pp. S215-S218. |
| Notification of Reasons for Rejection and English language translation issued in corresponding Japanese Patent Application No. 2015-517565, dated Mar. 28, 2017, 6 pages. |
| Onders R.,, “A Diaphragm Pacing as a Short-Term Assist to Positive Pressure Mechanical Ventilation in Critical Care Patients,” Chest, Oct. 24, 2007, vol. 132(4), pp. 5715-5728. |
| Onders R.,, “Diaphragm Pacing for Acute Respiratory Failure,” Difficult Decisions in Thoracic Surgery, Chapter 37, Springer-Verlag, 2011, M.K. Ferguson (ed.), pp. 329-335. |
| Onders R, et al., “Diaphragm Pacing with Natural Orifice Transluminal Endoscopic Surgery: Potential for Difficult-To-Wean Intensive Care Unit Patients,” Surgical Endoscopy, 2007, vol. 21, pp. 475-479. |
| Pavlovic D., et al., “Diaphragm Pacing During Prolonged Mechanical Ventilation of the Lungs could Prevent from Respiratory Muscle Fatigue,” Medical Hypotheses, vol. 60 (3), 2003, pp. 398-403. |
| Planas R.F., et al., “Diaphragmatic Pressures: Transvenous vs. Direct Phrenic Nerve Stimulation,” Journal of Applied Physiology, vol. 59(1), 1985, pp. 269-273. |
| Romanovsky, A.A., et al., “The Vagus Nerve in the Thermoregulatory Response to Systemic Inflammation,” American Journal of Physiology, vol. 273 (1 Pt 2), 1997, pp. R407-13. |
| Salmela L., et al., “Verification of the Position of a Central Venous Catheter by Intra-Atrial ECG. When does this method fail?,” Acta Anasthesiol Scand, vol. 37 (1), 1993, pp. 26-28. |
| Sandborn W.J., “Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis,” Annals of Internal Medicine, vol. 126 (5), Mar. 1, 1997, pp. 364-371. |
| Sandoval R., “A Catch/Ike Property-Based Stimulation Protocol for Diaphragm Pacing”, Master of Science Coursework project, Simon Fraser University, Mar. 2013. |
| Sarnoff, S.J. et al., “Electrophrenic Respiration,” Science, 1948, vol. 108, p. 482. |
| Sato E., et al., “Acetylcholine Stimulates Alveolar Macrophages to Release Inflammatory Cell Chemotactic Activity,” American Journal of Physiology, vol. 274 (Lung Cellular and Molecular Physiology 18), 1998, pp. L970-L979. |
| Sato, K.Z., et al., “Diversity of mRNA Expression for Muscarinic Acetylcholine Receptor Subtypes and Neuronal Nicotinic Acetylcholine Receptor Subunits in Human Mononuclear Leukocytes and Leukemic Cell Lines,” Neuroscience Letters, vol. 266 (1), 1999, pp. 17-20. |
| Schauerte P., et al., “Transvenous Parasympathetic Nerve Stimulation in the Inferior Vena Cava and Atrioventricular Conduction,” Journal of Cardiovascular Electrophysiology, vol. 11 (1), Jan. 2000, pp. 64-69. |
| Schauerte P.N., et al., “Transvenous Parasympathetic Cardiac Nerve Stimulation: An Approach for Stable Sinus Rate Control,” Journal of Cardiovascular Electrophysiology, vol. 10 (11), Nov. 1999, pp. 1517-1524. |
| Scheinman R.I., et al., “Role of Transcriptional Activation of IκBα in Mediation of Immunosuppression by Glucocorticoids,” Science, vol. 270, Oct. 13, 1995, pp. 283-286. |
| Sher, M.E., et al., “The Influence of Cigarette Smoking on Cytokine Levels in Patients with Inflammatory Bowel Disease,” Inflammatory Bowel Diseases, vol. 5 (2), May 1999, pp. 73-78. |
| Steinlein, O., “New Functions for Nicotinic Acetylcholine Receptors?,” Behavioural Brain Research, vol. 95, 1998, pp. 31-35. |
| Sternberg E.M., (Series Editor) “Neural-Immune Interactions in Health and Disease,” The Journal of Clinical Investigation, vol. 100 (11), Dec. 1997, pp. 2641-2647. |
| Sykes., A.P., et al., “An Investigation into the Effect and Mechanisms of Action of Nicotine in Inflammatory Bowel Disease,” Inflammation Research, vol. 49, 2000, pp. 311-319. |
| Toyabe S., et al., “Identification of Nicotinic Acetylcholine Receptors on Lymphocytes in the Periphery as well as Thymus in Mice,” Immunology, vol. 92, 1997, pp. 201-205. |
| Van Dijk A.P.M., et al., “Transdermal Nicotine Inhibits Interleukin 2 Synthesis by Mononuclear Cells Derived from Healthy Volunteers,” European Journal of Clinical Investigation, vol. 28, 1998, pp. 664-671. |
| Wanner, A. et al., “Trasvenous Phrenic Nerve Stimulation in Anesthetized Dogs,” Journal of Applied Physiology, 1973, vol. 34 (4), pp. 489-494. |
| Watkins L.R., et al., “Blockade of Interleukin-1 Induced Hyperthermia by Subdiaphragmatic Vagotomy: Evidence for Vagal Mediation of Immune-Brain Communication,” Neuroscience Letters, vol. 183, 1995, pp. 27-31. |
| Watkins L.R., et al., “Implications of Immune-to-Brain Communication for Sickness and Pain,” PNAS (Proceedings of the National Academy of Sciences of the USA), vol. 96 (14), Jul. 6, 1999, pp. 7710-7713. |
| Whaley K., et al., “C2 Synthesis by Human Monocytes is Modulated by a Nicotinic Cholinergic Receptor,” Nature, vol. 293, Oct. 15, 1981, pp. 580-582 (and reference page). |
| International Search Report dated Sep. 18, 2018 for PCT Application No. PCT/US2018/040185, 8 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20200188659 A1 | Jun 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62527536 | Jun 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16022897 | Jun 2018 | US |
| Child | 16802827 | US |
